NOTE:    The following Minutes are provided for informational purposes only.

If you would like to obtain an official copy of these Minutes, please contact the

State Board of Pharmacy at 614/466-4143 for instructions and fee.

 

Ohio State Board of Pharmacy   77 South High Street, Room 1702   Columbus, Ohio 43215-6126
telephone:  614-466-4143              fax:  614-752-4836            email:  exec@bop.state.oh.us

 

Minutes Of The Meeting

Ohio State Board of Pharmacy

Columbus, Ohio

April 3, 4, 5, 2000

 

MONDAY, APRIL 3, 2000

 

  8:15 a.m.      ROLL CALL

 

                     The State Board of Pharmacy convened in Room 1948, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio with the following members present:

 

                           Robert B. Cavendish, R.Ph. (President); Diane C. Adelman, R.Ph. (Vice-President); Ann D. Abele, R.Ph.; Suzanne R. Eastman, R.Ph.; Robert P. Giacalone, R.Ph.; Lawrence J. Kost, R.Ph.; Suzanne L. Neuber, R.Ph.; and Nicholas R. Repke, Public Member.

 

                     Also present were William T. Winsley, Executive Director; Timothy Benedict, Assistant Executive Director; David Rowland, Legal Affairs Administrator; and Sally Ann Steuk, Assistant Attorney General.

  8:20 a.m.

                     After a brief discussion regarding the schedule for reviewing and filing rules that the Board has followed for many years, the Board agreed that the normal public hearing on any rule changes or additions should be moved from the December meeting each year to the November meeting.  This should avoid many of the problems that have occurred in the past at the end of the calendar year with the annual reorganization of the Joint Committee on Agency Rule Review (JCARR).

  8:25 a.m.

                     The Board was joined by Charles Broussard of the Pharmacists Rehabilitation Organi­zation (PRO) for a discussion about the new laboratory procedures that would soon be implemented by PRO.  No formal action by the Board was required.

  9:00 a.m.

RES. 2000-135  Mr. Benedict discussed the electronic prescription delivery policies of ProxyMed as they related to both CVS.com and Allscripts.com.  The Board agreed that as long as there was a mechanism in place to protect the confidentiality of the patient records from unauthorized access, there did not appear to be any violations of pharmacy laws, rules, or regulations with this system.

  9:20 a.m.

                     The Board took a brief recess.

  9:35 a.m.

                     Ms. Abele moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code.  The motion was seconded by Mrs. Adelman and a roll call vote was conducted by President Cavendish as follows: Abele-Yes, Adelman-Yes, Eastman-Yes, Giacalone-Yes, Kost-Yes, Neuber-Yes, and Repke-Yes.

  9:52 a.m.

                     The Executive Session ended and the Board meeting resumed in Public Session.

 

RES. 2000-136  Ms. Abele then moved that, pursuant to Section 3719.121 of the Revised Code, the Board summarily suspend the license to practice pharmacy belonging to Joseph R. Tabler, R.Ph. (03-1-07832) due to the fact that a continuation of his professional practice presents a danger of immediate and serious harm to others.  The motion was seconded by Mr. Giacalone and approved by the Board (Aye-7/Nay-0).

  9:55 a.m.

RES. 2000-137  William McMillen, Licensing Administrator, joined the Board and presented a request for an exemption from Rule 4729-5-10 (Pick-up station) that had been received from Mount Auburn Health Center Pharmacy and its associated clinics.  After discussion, Ms. East­man moved that the Board approve the exemption request.  The motion was seconded by Mr. Giacalone and approved by the Board (Aye-7/Nay-0).

 

RES. 2000-138  Mr. Winsley requested Board approval to renew the contract with the National Associa­tion of Boards of Pharmacy for the printing of the quarterly newsletter.  Mrs. Adelman moved that the Board approve the continuation of this contract.  The motion was seconded by Mr. Giacalone and approved by the Board (Aye-7/Nay-0).

10:00 a.m.

                     The Board took a brief recess.

10:16 a.m.

                     The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Charles R. Mohr, Wadsworth, Ohio.

12:39 p.m.

                     Board member Amonte Littlejohn arrived and joined the meeting.  Mr. Cavendish announced that Mr. Littlejohn would not participate in the hearing and he would not participate in the discussion or deliberations that followed.

  1:12 p.m.

                     The hearing concluded and the record was closed.  Mr. Repke moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code.  The motion was seconded by Mrs. Adelman and a roll call vote was conducted by President Cavendish as follows: Abele-Yes, Adelman-Yes, Eastman-Yes, Giacalone-Yes, Kost-Yes, Littlejohn-Yes, Neuber-Yes, and Repke-Yes.

  1:17 p.m.

                     The Executive Session ended and the Board meeting resumed in Public Session.

 

RES. 2000-139  Mr. Littlejohn then moved that, pursuant to Section 3719.121 of the Revised Code, the Board summarily suspend the license to practice pharmacy belonging to Katherine Blair, R.Ph. (03-2-16954) due to the fact that a continuation of her professional practice presents a danger of immediate and serious harm to others.  The motion was seconded by Mrs. Adelman and approved by the Board (Aye-8/Nay-0).

  1:18 p.m.

                     The Board recessed for lunch.

  2:35 p.m.

                     The meeting resumed in Room 1948, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio with all of the Board members present.  Mr. Repke moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code and for the purpose of conferring with an attorney for the Board regarding pending or imminent court action pursuant to Section 121.22(G)(3) of the Revised Code.  The motion was seconded by Mr. Littlejohn and a roll call vote was conducted by President Cavendish as follows: Abele-Yes, Adelman-Yes, Eastman-Yes, Giacalone-Yes, Kost-Yes, Littlejohn-Yes, Neuber-Yes, and Repke-Yes.

  4:00 p.m.

                     The Executive Session ended and the Board meeting resumed in Public Session.

 

RES. 2000-140  Mrs. Neuber moved that the Board deny the proposed settlement offer presented in the matter of James Bayless, R.Ph. and that the hearing be held as scheduled.  The motion was seconded by Mr. Repke and approved by the Board (Aye-8/Nay-0).

 

RES. 2000-141  Ms. Eastman then moved that the Board approve a revised settlement offer with Newtown Fire and Rescue.  The settlement will become official after it is signed by all parties.  The motion was seconded by Mr. Giacalone and approved by the Board (Aye-8/Nay-0).

 

RES. 2000-142  Ms. Eastman moved that the Board deny the proposed settlement offer presented in the matter of Frank Lancz, R.Ph. and that the hearing be held as scheduled.  The motion was seconded by Mr. Kost and approved by the Board (Aye-8/Nay-0).

 

RES. 2000-143  Mrs. Neuber moved that the Board deny the request for reconsideration of the Board Order issued in the matter of Gary Gerst effective November 15, 1999.  The motion was seconded by Ms. Eastman and approved by the Board (Aye-8/Nay-0).

 

RES. 2000-144  Mrs. Neuber then moved that the Board issue the following Order in the matter of Charles R. Mohr:

 

ORDER OF THE STATE BOARD OF PHARMACY

(Docket No. D-991228-039)

 

In The Matter Of:

 

CHARLES R. MOHR

6526 Burdett Road

Wadsworth, Ohio  44281

(D.O.B. 2/2/57)

 

INTRODUCTION

 

THE MATTER OF CHARLES R. MOHR CAME TO HEARING ON APRIL 3, 2000, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: ROBERT B. CAVENDISH, R.Ph. (presiding); ANN D. ABELE, R.Ph.; DIANE C. ADELMAN, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; LAWRENCE J. KOST, R.Ph.; SUZANNE L. NEUBER, R.Ph.; AND NICHOLAS R. REPKE, PUBLIC MEMBER.

 

CHARLES R. MOHR WAS REPRESENTED BY TIMOTHY H. CHAMPION, AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.

 

SUMMARY OF EVIDENCE

 

(A)     Testimony

 

         State's Witnesses:

 

(1)      Joann Predina, Ohio State Board of Pharmacy

 

         Respondent's Witnesses:

 

(1)      Charles R. Mohr, Respondent

(2)      Albert Weinstein, Pharmacists Rehabilitation Organization

(3)      Kim Snodgrass, Alcoholics Anonymous Sponsor

 

(B)      Exhibits

 

         State's Exhibits:

 

(1)      Exhibit 1--Copy of three-page Proposal to Deny Exam Application/Notice of Opportunity for a Hearing letter dated December 28, 1999.

(2)      Exhibit 1A--Hearing Request letter dated January 6, 2000.

(3)      Exhibit 1B--Copy of Hearing Schedule letter dated January 14, 2000.

(4)      Exhibit 1C

(5)      Exhibit 1D--Copy of Pharmacist File Front Sheet of Charles Richard Mohr showing original date of registration as March 1, 1984.

(6)      Exhibit 1E

(7)      Exhibit 1F

(8)      Exhibit 2--Copy of Akron General Medical Center Discharge Summary of Charles Mohr for the period May 2, 1993, to May 8, 1993.

(9)      Exhibit 2A--Copy of six-page Order of the State Board of Pharmacy, Docket No. D-940201-043, effective August 15, 1994.

(10)    Exhibit 3--Copy of four-page Order of the State Board of Pharmacy, Docket No. D-970117-026, effective October 8, 1997.

(11)    Exhibit 5

(12)    Exhibit 6

(13)    Exhibit 7--Copy of three-page statement of Rebecca Infantino, R.Ph. dated September 2, 1993.

(14)    Exhibit 8--Statement of Donald Gale, R.Ph. dated September 2, 1993.

 

         Respondent's Exhibits:

 

         Spiral-bound folder with Table of Contents and tabbed dividers marked A through F containing the following:

 

(1)      Exhibit A1--Copy of two-page Pharmacist's Recovery Contract for Charles R. Mohr dated January 9, 1997.

(2)      Exhibit B1--Copy of letter from John M. Surso dated August 4, 1997.

(3)      Exhibit B2--Copy of Drug Screen Collection Procedure signed by John M. Surso, M.D.

(4)      Exhibits B2A through B53--Copies of Urine Drug Screen Reports of Charles R. Mohr for collection dates: March 6, 2000; February 22, 2000; January 25, 2000; December 16, 1999; November 11, 1999; October 27, 1999; September 28, 1999; September 10, 1999; August 27, 1999; July 26, 1999; June 30, 1999; May 25, 1999; April 20, 1999; March 26, 1999; February 16, 1999; January 27, 1999; December 31, 1998; November 12, 1998; October 26, 1998; September 23, 1998; August 4, 1998; July 17, 1998; June 29, 1998; May 27, 1998; April 28, 1998; March 25, 1998; February 26, 1998; January 28, 1998; December 19, 1997; November 17, 1997; October 16, 1997; September 26, 1997; July 22, 1997; May 27, 1997; March 13, 1997; January 27, 1997; December 5, 1996; October 15, 1996; September 17, 1996; August 29, 1996; June 25, 1996;
May 25, 1996; February 28, 1996; November 27, 1995; September 27, 1995; August 28, 1995; July 1, 1995; May 1, 1995; March 20, 1995; February 13, 1995; December 16, 1994; November 30, 1994; and March 28, 1996.

(5)      Exhibits C1 through C28--Copy of twenty-eight pages of Meeting Attendance Verification sheets with dates from June 1, 1994, through March 28, 2000.

(6)      Exhibit D1--Copy of letter from John Bukovesky dated March 15, 2000.

(7)      Exhibit D2--Copy of Earnings Statement of Charles R. Mohr at Inflatable Survival Systems, Inc. for the pay period ending March 15, 2000.

(8)      Exhibit D3--Copy of letter from Robert C. Burns dated March 30, 2000.

(9)      Exhibit D4--Copy of letter from David P. Tenley dated March 30, 2000.

(10)    Exhibits D5 and D6--Copy of two-page letter from Kim K. Snodgrass dated August 14, 1997.

(11)    Exhibit D7--Copy of unfinished letter not signed dated August 6, 1997.

(12)    Exhibits D8 and D9--Copy of two-page letter from Rev. J. Norman Riley dated August 9, 1997.

(13)    Exhibit D10--Copy of letter from Doug Potts dated August 10, 1997.

(14)    Exhibit D11--Copy of letter from Albert Weinstein dated August 11, 1997.

(15)    Exhibit D12--Copy of letter from Bernadette Skoula dated August 18, 1997.

(16)    Exhibit D13--Copy of letter from Michael F. Cassidy not dated.

(17)    Exhibit D14--Copy of letter from Dave Tenley dated August 23, 1997.

(18)    Exhibit D15--Copy of letter from Theron R. Brayman dated August 22, 1997.

(19)    Exhibit E1

(20)    Exhibit E2

(21)    Exhibit E3

(22)    Exhibits E4, E5, and E6

(23)    Exhibits F1 through F15--Fifteen pages of copies of continuing pharmacy education certificates of Charles R. Mohr for programs numbered and dated as follows: 036-106-99-004-L01 and 036-106-99-005-L03-J dated May 16, 1999; 751-000-99-010-L01 dated May 7, 1999; 129-000-97-003-H01 and 129-000-97-004-H01 dated March 11, 1999; 424-000-98-014-H01 dated January 20, 1999; 036-162-98-001-J dated March 8, 1998; 129-000-96-001-H01, 129-000-96-002-H01, 129-000-96-003-H01, 129-000-96-004-H01, 129-000-96-005-H01, 129-000-96-006-H01, 129-000-97-005-H01, 129-000-97-006-H01, and 129-000-97-007-H01 dated August 6, 1997; 129-000-96-007-H01, 129-000-96-008-H01, 129-000-96-009-H01, 129-000-96-010-H01, and 129-000-97-001-H01 dated August 11, 1997; 057-999-97-048-H04 dated October 1, 1997; 202-000-98-094-H01 dated September 1998; 810-000-96-001-L04 dated October 23, 1996; 802-000-95-010-L04 dated April 10, 1996; two numbered 129-000-96-047-L04 dated November 1, 1996; 692-424-94-019 dated April 3, 1995; Drug-Nutrient Interactions (program number illegible) dated April 3, 1995; 180-029-92-005 dated August 16, 1993; 189-761-92-009 dated July 19, 1993; and 680-026-91-032 dated June 1993.

 

FINDINGS OF FACT

 

After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the following to be fact:

 

(1)      Records of the State Board of Pharmacy indicate that Charles R. Mohr submitted an application for examination as a pharmacist on or about December 23, 1999.

 

(2)      Records further indicate that Charles R. Mohr was originally licensed to practice pharmacy in the state of Ohio on March 1, 1984.  Charles R. Mohr’s license was summarily suspended on February 1, 1994.  A hearing was held in accordance with Chapter 119. of the Ohio Revised Code on April 15, 1994, and reconvened on June 27, 1994.

 

(3)      On or about August 15, 1994, the Board found the following to be fact:

 

(a)      Charles R. Mohr was originally registered to practice pharmacy in the state of Ohio on March 1, 1984, pursuant to examination, and his pharmacist identification card was summarily suspended on February 1, 1994.

 

(b)     

 

(c)     

 

(d)      Charles R. Mohr was addicted to or abusing liquor or drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy, to wit:  Charles R. Mohr admitted to hav­ing two previous problems with abuse of Xanax, in 1987, and again in 1989; he admitted to having a first and second relapse in his drug usage after drug treatment.

 

         The Board concluded that Charles R. Mohr was                   ; guilty of dishonesty and unprofessional conduct in the practice of pharmacy; addicted to and abusing drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy; and guilty of willfully violating, conspir­ing to violate, attempting to violate, or aiding and abetting the violation of provisions of Chapters 2925., 3719., or 4729. of the Revised Code within the meaning of Section 4729.16 of the Ohio Revised Code.  The Board revoked Charles R. Mohr's license, No. 03-2-15404, to practice pharmacy in the state of Ohio.

 

(4)      Records of the Board further indicate that Charles R. Mohr submitted an Appli­cation for Examination as a Pharmacist on or about October 15, 1996; and on or about October 8, 1997, for the reasons stated in paragraph (3) above, his application was denied.

 

CONCLUSIONS OF LAW

 

(1)     

 

(2)     

 

(3)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraphs (3)(b) through (3)(d) of the Findings of Fact constitute not being of good moral character and habits as provided in paragraph (C) of Rule 4729-5-04 the Ohio Administrative Code.

 

(4)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraph (3)(d) of the Findings of Fact constitutes being addicted to or abusing liquor or drugs as provided in paragraph (D) of Rule 4729-5-04 of the Ohio Administrative Code.

 

(5)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraph (3) of the Findings of Fact constitutes having been dis­ciplined by the Ohio State Board of Pharmacy pursuant to Section 4729.16 of the Revised Code as provided in paragraph (E) of Rule 4729-5-04 of the Ohio Administrative Code.

 

ACTION OF THE BOARD

 

Pursuant to Section 4729.08 of the Ohio Revised Code and Rule 4729-5-04 of the Ohio Administrative Code, and on the basis of the foregoing Findings of Fact and Conclusions of Law, the State Board of Pharmacy hereby denies the issuance of a certificate of registra­tion or an identification card to practice pharmacy and, therefore, denies the Application for Examination as a Pharmacist submitted by Charles R. Mohr.

 

THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY.

MOTION CARRIED.

SO ORDERED.

 

                     The motion was seconded by Ms. Abele and approved by the Board (Aye-4/Nay-3/­Abstain-1[Littlejohn]).

  4:30 p.m.

                     The Board meeting recessed until Tuesday, April 4, 2000.

 

 

TUESDAY, april 4, 2000

 

  8:35 a.m.      ROLL CALL

 

                     The State Board of Pharmacy convened in Room 1948, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio with the following members present:

 

                           Robert B. Cavendish, R.Ph. (President); Diane C. Adelman, R.Ph. (Vice-President); Ann D. Abele, R.Ph.; Suzanne R. Eastman, R.Ph.; Robert P. Giacalone, R.Ph.; Lawrence J. Kost, R.Ph.; Amonte B. Littlejohn, R.Ph.; Suzanne L. Neuber, R.Ph.; and Nicholas R. Repke, Public Member.

  8:37 a.m.

                     Ms. Abele moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code.  The motion was seconded by Mrs. Adelman and a roll call vote was conducted by President Cavendish as follows: Abele-Yes, Adelman-Yes, Eastman-Yes, Giacalone-Yes, Kost-Yes, Littlejohn-Yes, Neuber-Yes, and Repke-Yes.

  8:54 a.m.

RES. 2000-145  The Executive Session ended and the meeting was opened to the public.  Mrs. Neuber then moved that, pursuant to Section 3719.121 of the Revised Code, the Board sum­marily suspend the license to practice pharmacy belonging to Randolph Mosier, R.Ph. (03-1-20467) due to the fact that a continuation of his professional practice presents a danger of immediate and serious harm to others.  The motion was seconded by Mr. Kost and approved by the Board (Aye-8/Nay-0).

 

RES. 2000-146  After a discussion of a request received from Walter Hubish regarding his Board Order, Mr. Benedict was instructed by the Board to inform Mr. Hubish that he must comply with his Board Order as it was written.

  8:57 a.m.

                     The Board took a brief recess.

  9:17 a.m.

                     The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Robert Frank Tschinkel, R.Ph., Hudson, Ohio.

10:50 a.m.

                     The hearing concluded and the record was closed.

11:08 a.m.

                     Mr. Benedict reported to the Board on discussions he had held with representatives from Ortho-McNeil regarding the use of coupons instead of drug samples for certain products.  There was no formal action required by the Board on this matter.

11:18 a.m.

                     Ms. Abele moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code.  The motion was seconded by Mrs. Adelman and a roll call vote was conducted by President Cavendish as follows: Abele-Yes, Adelman-Yes, Eastman-Yes, Giacalone-Yes, Kost-Yes, Littlejohn-Yes, Neuber-Yes, and Repke-Yes.

11:33 a.m.

RES. 2000-147  The Executive Session ended and the meeting was opened to the public.  Mr. Littlejohn then moved that, pursuant to Section 3719.121 of the Revised Code, the Board sum­marily suspend the license to practice pharmacy belonging to Derek Duckworth, R.Ph. (03-2-10274) due to the fact that a continuation of his professional practice presents a danger of immediate and serious harm to others.  The motion was seconded by Mrs. Neuber and approved by the Board (Aye-8/Nay-0).

11:38 a.m.

RES. 2000-148  Mrs. Neuber then moved that the Board adopt the following Order in the matter of Robert Frank Tschinkel, R.Ph.:

 

ORDER OF THE STATE BOARD OF PHARMACY

(Docket No. D-991214-038)

 

In The Matter Of:

 

ROBERT FRANK TSCHINKEL, R.Ph.

2377 Hudson Aurora Road

Hudson, Ohio  44236

(R.Ph. No. 03-1-10969)

 

INTRODUCTION

 

THE MATTER OF ROBERT FRANK TSCHINKEL CAME FOR HEARING ON APRIL 4, 2000, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: ROBERT B. CAVENDISH, R.Ph. (pre­siding); ANN D. ABELE, R.Ph.; DIANE C. ADELMAN, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; LAWRENCE J. KOST, R.Ph.; AMONTE B. LITTLEJOHN, R.Ph.; SUZANNE L. NEUBER, R.Ph.; AND NICHOLAS R. REPKE, PUBLIC MEMBER.

 

ROBERT FRANK TSCHINKEL WAS REPRESENTED BY ROBERT J. GARRITY, AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.

 

SUMMARY OF EVIDENCE

 

(A)     Testimony

 

         State's Witnesses:

 

(1)      James Reye, Ohio State Board of Pharmacy

 

         Respondent's Witnesses:

 

(1)      Robert Frank Tschinkel, Respondent

(2)      David Merk, Pharmacists Rehabilitation Organization

(3)      David W. Baker, Pharmacists Rehabilitation Organization

 

(B)      Exhibits

 

         State's Exhibits:

 

(1)      Exhibit 1--Copy of four-page Summary Suspension Order/Notice of Opportunity for Hearing letter dated December 14, 1999.

(2)      Exhibit 1A

(3)      Exhibit 1B--Copy of Hearing Schedule letter dated January 7, 2000.

(4)      Exhibit 1C--Robert Frank Tschinkel Settlement Offer submitted by Robert J. Garrity, Esq., dated January 13, 2000.

(5)      Exhibit 1D--Copy of Letter to Deny Settlement Offer dated February 7, 2000.

(6)      Exhibit 1E--Copy of Pharmacist File Front Sheet of Robert Frank Tschinkel show­ing original date of registration as July 30, 1974; and two-page copy of Renewal Application for Pharmacist License, No. 03-1-10969, for a license to practice pharmacy from September 15, 1999, to September 15, 2000, of Robert Frank Tschinkel dated July 15, 1999.

(7)     

(8)     

(9)      Exhibit 4--Two-page hand-written notes regarding Robert Frank Tschinkel dated December 3, 1999.

(10)   

(11)   

(12)   

 

         Respondent's Exhibits:

 

         Three-prong folder with Table of Contents page and tabbed dividers containing the following:

 

(1)      Exhibit A

(2)      Exhibit B

(3)      Exhibit C--Copy of Glenbeigh Continuing Recovery Plan of Robert F. Tschinkel dated December 15, 1999; and copy of Glenbeigh Continuing Care Progress Report of Robert Tschinkel dated March 24, 2000.

(4)      Exhibit D--Two-page copy of Pharmacist's Recovery Contract of Bob Tschinkel dated December 8, 1999 by sponsor Tim Moran; and two-page copy of Pharma­cist's Recovery contract of Bob Tschinkel dated December 8, 1999 by sponsor Scott Jordan.

(5)      Exhibit E--Copy of five pages of AA/NA Attendance Verification sheets of Robert F. Tschinkel dated November 10, 1999 through April 1, 2000.

(6)      Exhibit F--Copy of four urine drug screen reports and observed urine sample verifications dated December 9, 1999; January 28, 2000; February 29, 2000; and March 22, 2000.

(7)      Exhibit G--Copy of ten letters from: Scott Jordan dated April 3, 2000; anony­mous author dated April 3, 2000; Michael Bukach dated April 2, 2000; Christine R. Spiroch dated April 1, 2000; Daniel H. Tedick dated March 29, 2000; Dennis and Patricia Macko not dated; Patty J. Baxter dated March 30, 2000; Todd R. Jaros dated March 26, 2000; S. M. Conroy dated April 2, 2000; Thomas F. Tschinkel dated April 1, 2000.

(8)      Exhibit H--Copy of Resume of Robert F. Tschinkel; copy of Certificate of Appreciation from Downtown Golden Age Center dated March 1993; five pages consisting of copies of continuing pharmacy education certificates for programs numbered: 129-000-99-047-H03; 129-000-99-011-H01; 129-000-99-012-H01; 129-000-99-048-H03; 129-000-00-001-H01; 129-000-00-002-H01; 129-000-98-049-H03; 202-000-97-073-H01; 422-000-98-011-H01; 422-000-98-012-H01; 422-000-98-013-H01; 422-000-98-014-H01; 327-000-97-001-H04; 424-000-99-002-H03; 424-000-99-003-H01; 356-000-99-011-H01; 207-000-98-012-H01; 088-999-99-004-H01; and copy of Certificate of Attendance for Summit on Cholesterol and Coronary Disease dated September 2-3, 1999.

 

FINDINGS OF FACT

 

After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the following to be fact:

 

(1)      Records of the State Board of Pharmacy indicate that Robert Frank Tschinkel was originally licensed in the state of Ohio on July 30, 1974, pursuant to exami­nation.  On December 14, 1999, Robert Frank Tschinkel’s license to practice pharmacy in the state of Ohio was suspended in accordance with Divisions (A) and (B) of Section 3719.121 of the Ohio Revised Code.

 

(2)      Robert Frank Tschinkel is addicted to liquor or drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy, to wit: Robert Frank Tschinkel admitted stealing controlled substances from his employer, Medic Discount Drug #292, and he has practiced pharmacy while being impaired; Robert Frank Tschinkel admitted that he is “psychologically addicted” to the drugs he was stealing; and, he is currently involved in an outpatient drug treatment program.  Such conduct indicates that Robert Frank Tschinkel falls within the ambit of Sections 3719.121(A), 3719.121(B), and 4729.16(A)(3) of the Ohio Revised Code.

 

(3)      Robert Frank Tschinkel did, from on or about August 1, 1998, through Septem­ber 8, 1999, with purpose to deprive, knowingly obtain or exert control over dangerous drugs, the property of Medic Discount Drug #292, beyond the express or implied consent of the owner, to wit: by his own admission, through­out this time period, Robert Frank Tschinkel stole the following drugs:

 

                                                                                            Approximated

                                     Drug                                                    Quantity

                     Hydrocodone 10mg/APAP 650mg                             50

                     Alprazolam 1mg                                                      560

                     Alprazolam .5mg                                                     560

                     Vicodin ES (brand and generic)                                   50

                     Vicoprofen                                                              200

                     Lorcet Plus tablets                                                     50

                     Lorcet tablets                                                            50

                     Fiorinal/Codeine #3                                                   40

                     Fioricet/Codeine #3                                                   30

                     Topicort Cream                                                           1

                     Prenatal Vitamins                                                         1

                     Amoxicillin 500mg                                                    40

                     Atenolol                                                                  200

 

         Such conduct is in violation of Section 2913.02 of the Ohio Revised Code.

 

(4)      Robert Frank Tschinkel did, from on or about January 1, 1999, through September 8, 1999, with purpose to deprive, knowingly obtain or exert control over dangerous drugs, the property of Medic Discount Drug #292, beyond the express or implied consent of the owner, to wit: by his own admission, throughout this time period, Robert Frank Tschinkel stole the following drugs:

 

                                                                                            Approximated

                              Drug                                                           Quantity

                     Fioricet (generic)                                                         540

                     Fiorinal (generic)                                                         540

 

         Such conduct is in violation of Section 2913.02 of the Ohio Revised Code.

 

(5)      Robert Frank Tschinkel did, from on or about August 1, 1998, through September 8, 1999, with purpose to deprive, knowingly obtain or exert control over the property of Medic Discount Drug #292, beyond the express or implied consent of the owner, to wit: by his own admission, throughout this time period, Robert Frank Tschinkel stole an amount less than $500.00 worth of non-pharmaceutical items from the front-end of Medic Discount Drug #292.  Such conduct is in violation of Section 2913.02 of the Ohio Revised Code.

 

CONCLUSIONS OF LAW

 

(1)     

 

(2)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraphs (2) through (5) of the Findings of Fact constitute being guilty of dishonesty and unprofessional conduct in the practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.

 

(3)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraph (2) of the Findings of Fact constitutes being addicted to or abusing liquor or drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy as provided in Division (A)(3) of Section 4729.16 of the Ohio Revised Code.

 

(4)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraph (2) of the Findings of Fact constitutes being guilty of willfully violating, conspiring to violate, attempting to violate, or aiding and abetting the violation of provisions of Chapters 3719. and 4729. of the Revised Code as provided in Division (A)(5) of Section 4729.16 of the Ohio Revised Code.

 

ACTION OF THE BOARD

 

Pursuant to Section 3719.121 of the Ohio Revised Code, the State Board of Pharmacy hereby removes the Summary Suspension Order issued  December 14, 1999.

 

Pursuant to Section 4729.16 of the Ohio Revised Code, and on the basis of the Findings
of Fact and Conclusions of Law set forth above, the State Board of Pharmacy hereby suspends indefinitely the pharmacist identification card, No. 03-1-10969, held by Robert Frank Tschinkel and such suspension is effective as of the date of the mailing of this Order.

 

(A)     Robert Frank Tschinkel, pursuant to Rule 4729-9-01(F) of the Ohio Administra­tive Code, may not be employed by or work in a facility licensed by the Board
of Pharmacy to possess or distribute dangerous drugs during such period of suspension.

 

(B)      Robert Frank Tschinkel, pursuant to Section 48729.16(B) of the Ohio Revised Code, must return the identification card and wall certificate to the office of the State Board of Pharmacy within ten days after receipt of this Order.  The identi­fication card and wall certificate should be forwarded by certified mail, return receipt requested.

 

Further, on or after January 1, 2002, the Board will consider any petition filed by Robert Frank Tschinkel for a hearing, pursuant to Ohio Revised Code Chapter 119., for reinstate­ment.  The Board will only consider reinstatement of the license to practice pharmacy in Ohio if the following conditions have been met:

 

(A)     Robert Frank Tschinkel must obtain, within ninety days after the effective date of this Order, a full psychiatric or psychological evaluation, by a licensed psychiatrist or psychologist, that includes a recommended treatment plan.  Robert Frank Tschinkel must abide by the treatment plan as designed by that psychiatrist or psychologist.

 

(B)      Robert Frank Tschinkel must enter into a contract, signed within ninety days after the effective date of this Order, with an Ohio Department of Alcohol and Drug Addiction Services (ODADAS) treatment provider or a treatment provider acceptable to the Board for a period of not less than five years.  The contract must provide that:

 

(1)      Random, observed urine drug screens shall be conducted at least once each month.

 

(a)      The urine sample must be given within twelve hours of notification.  The urine screen must include testing for creatinine or specific gravity of the sample as the dilutional standard.

 

(b)      Alcohol must be added to the standard urine drug screen.  A Breathalyzer may be used to test for alcohol, but the test must be conducted by an appropriately certified individual within twelve hours of notification.

 

(c)      Results of all drug and alcohol screens must be negative.  Any positive results, including those which may have resulted from ingestion of food, but excluding false positives which resulted from medication legitimately prescribed, indicates a violation of the contract.

 

(2)      Regular attendance, a minimum of three times per week, at an Alcoholics Anonymous, Narcotics Anonymous, and/or similar support group meeting is required.

 

(3)      The program shall immediately report to the Ohio Board of Pharmacy any violations of the contract and/or lack of cooperation.

 

(C)      Robert Frank Tschinkel must provide, at the reinstatement petition hearing, documentation of the following:

 

(1)      Compliance with the licensed psychiatrist's or psychologist's recom­mended treatment plan.

 

(2)      A report by the licensed psychiatrist or psychologist regarding Robert Frank Tschinkel's fitness for readmission into the practice of phar­macy.

 

(3)      Compliance with the contract required above (e.g. proof of giving the urine sample within twelve hours of notification, copies of all urine screen reports, meeting attendance records, treatment program reports, etc.).

 

(4)      Compliance with the continuing pharmacy education requirements as set forth in Chapter 4729-7 of the Ohio Administrative Code.

 

(5)      Compliance with the terms of this Order.

 

(D)     The intervenor assigned to Robert Frank Tschinkel must appear and testify before the Board at the reinstatement petition hearing.

 

(E)      If reinstatement is not accomplished within three years of the effective date of this Order, Robert Frank Tschinkel must show successful completion of the NAPLEX examination or an equivalent examination approved by the Board.

 

THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY.

MOTION CARRIED.

SO ORDERED.

 

                     The motion was seconded by Mr. Littlejohn and approved by the Board (Aye-8/Nay-0).

11:43 a.m.

                     The Board recessed for lunch.

  1:00 p.m.

RES. 2000-149  All of the Board members convened in Room West B & C on the 31st floor of the Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio for the purpose of meeting with the candidates for licensure by reciprocity.  Following presen­tations by Board members and self-introductions by the candidates for licensure by reciprocity, Mrs. Adelman moved that the Board approve the following candidates for licensure.  The motion was seconded by Mr. Littlejohn and approved by the Board
(Aye-8/Nay-0).

 

      MICHELLE ADINA DAGANI                          03-3-24042                  CONNECTICUT

      THOMAS PETER DROUGAS                         03-3-24031                  MASSACHUSETTS

      ANGELA LYNN ELVERS                               03-3-24027                  TENNESSEE

      MAURA GAYLE JOHNSON                           03-3-24044                  INDIANA

      TAMMY SUE JOHNSON                               03-3-24048                  PENNSYLVANIA

      DONNA MARIE LUTZ                                  03-3-24036                  PENNSYLVANIA

      MARK EDWARD MAHONEY                        03-3-24009                  MASSACHUSETTS

      JOHANNA ELIZABETH QUINN                      03-3-24004                  SOUTH CAROLINA

      EDWARD THOMAS ROCERETA                    03-3-24023                  PENNSYLVANIA

      DAVID LEE TROSETH                                  03-3-24034                  MICHIGAN

      STEVE WESLEY WILD                                  03-3-23953                  SOUTH CAROLINA

      KARRIANN KYLE WOOD                             03-3-24030                  KENTUCKY

  1:40 p.m.

                     The Board reconvened in Room 1948 to continue with the Board meeting with all members present except Mr. Littlejohn and Mrs. Adelman.  The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudi­cation hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Michael Popovich, R.Ph., Weirton, West Virginia.

  1:51 p.m.

                     Mrs. Adelman and Mr. Littlejohn joined the meeting in progress.  Mr. Cavendish announced that neither member would participate in the hearing nor would they participate in the discussion and deliberations that would follow.

  3:10 p.m.

                     The hearing concluded and the record was closed.

  3:18 p.m.

                     Mr. Benedict, Mr. Winsley, and the Board then discussed current and pending legisla­tive issues.  There were no issues requiring formal action by the Board.

  3:50 p.m.

                     Mr. Repke moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code.  The motion was seconded by Ms. Eastman and a roll call vote was conducted by President Cavendish as follows: Abele-Yes, Adelman-Yes, Eastman-Yes, Giacalone-Yes, Littlejohn-Yes, Neuber-Yes, Kost-Yes, and Repke-Yes.

  4:12 p.m.

RES. 2000-150  The Executive Session ended and the meeting was opened to the public.  Mr. Repke moved that the Board adopt the following Order in the matter of Michael Popovich, R.Ph.:

 

ORDER OF THE STATE BOARD OF PHARMACY

(Docket No. D-000210-045)

 

In The Matter Of:

 

MICHAEL POPOVICH, R.Ph.

119 Greenlawn Boulevard

Weirton, West Virginia 26062

(R.Ph. No. 03-1-06619)

 

INTRODUCTION

 

THE MATTER OF MICHAEL POPOVICH CAME FOR CONSIDERATION ON APRIL 4, 2000 BEFORE THE FOLLOWING MEMBERS OF THE BOARD: ROBERT B. CAVENDISH, R.Ph. (pre­siding); ANN D. ABELE, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; LAWRENCE J. KOST, R.Ph.; SUZANNE L. NEUBER, R.Ph.; AND NICHOLAS R. REPKE, PUBLIC MEMBER.

 

MICHAEL POPOVICH WAS NOT PRESENT, NOR WAS HE REPRESENTED BY COUNSEL, AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.

 

SUMMARY OF EVIDENCE

 

(A)     Testimony

 

         State's Witnesses:

 

(1)      George Pavlich, Ohio State Board of Pharmacy

 

         Respondent's Witnesses:

 

(1)      None

 

(B)      Exhibits

 

         State's Exhibits:

 

(1)      Exhibit 1--Copy of nine-page Summary Suspension Order/Notice of Opportunity for Hearing letter dated February 10, 2000.

(2)      Exhibit 1A--Copy of Pharmacist File Front Sheet of Michael Popovich showing original date of registration as November 5, 1957.

(3)      Exhibit 1B--Two-page copy of Renewal Application for Pharmacist License, No. 03-1-06619, for a license to practice pharmacy in Ohio from September 15, 1999, to September 15, 2000, of Michael Popovich dated July 6, 1999.

(4)      Exhibit 1C--Copy of Renewal Application for DDD License, No. 02-0123650, for a Terminal Distributor of Dangerous Drugs license from January 1, 2000, to December 31, 2000, of Mikes Rexall Pharmacy signed by Michael Popovich on September 12, 1999.

(5)      Exhibit 1D--Copy of Renewal Application for DDD License, No. 02-0123650, for a Terminal Distributor of Dangerous Drugs license from January 1, 2000, to December 31, 2000, of Mikes Rexall Pharmacy signed by Michael Popovich on September 12, 1999.

(6)      Exhibit 1E--Copy of Terminal Distributor Notification of Change of Responsible Person form of Mike’s Rexall Pharmacy, Terminal Distributor No. 02-0123650, showing Justin A. Scarpone as responsible person, effective March 6, 2000; and, copy of Written Notice of Discontinuing Business form of Mikes Rexall Phar­macy, Terminal Distributor No. 02-0123650, showing date of discontinuation as March 31, 2000.

(7)      Exhibit 2--Two-page copy of Dangerous Drug Distributor, No. 02-0123650, licensing information report dated March 12, 1998; copy of Listing of Phar­macists/Interns employed at Specific Site: 02-0123650, report dated March 12, 1998; copies of nine pages of Dangerous Drug Distributor Inspection Reports for Mikes Rexall Pharmacy dated March 22, 1982; March 28, 1983; August 8, 1984; August 17, 1989; three pages dated December 12, 1991; November 2, 1992; and two pages dated May 3, 1994; and copy of letter from Michael Popovich dated May 18, 1994.

(8)      Exhibit 3--Prescription vial with Mike’s Pharmacy label containing 24 sample tablets of Monopril 10mg with the word “Sample” crudely scraped off the tab­lets; prescription vial containing 94 sample tablets of Monopril 10mg with the word “Sample” crudely scraped off the tablets; and prescription vial containing small piece of paper labeled “Soma Compound” and 80 sample tablets of Soma Compound 200/325 with the word “Sample” crudely scraped off the tablets.

(9)      Exhibit 4--Two starter sample vials of SYN-Rx DM tablets with physician label.

(10)    Exhibit 5--Copy of six-page Dangerous Drug Distributor Inspection Report of Mikes Rexall Pharmacy, Terminal Distributor No. 02-0123650, dated March 30, 1998.

(11)    Exhibit 6--Copy of six-page list of adulterated drugs, sample drugs, and out­dated drugs removed from Mike’s Pharmacy, Case No. 98-1192.

(12)    Exhibit 7--Copy of fourteen-page Dangerous Drug Distributor Inspection Report of Mikes Rexall Pharmacy, Terminal Distributor No. 02-0123650, dated April 1, 1998.

(13)    Exhibit 8--Copy of twelve-page response to the “Pink Sheet” violations recorded on the April 1, 1998, Dangerous Drug Distributor Inspection Report of Mikes Rexall Pharmacy signed by Michael Popovich and Nick Strovilas on April 1, 1998.

(14)    Exhibit 9--Twenty-page copy of Ohio State Board of Pharmacy Report of Investi­gation regarding the Statement of Michael Popovich, signed and notarized on November 15, 1999.

(15)    Exhibit 10-Five-page copy of Ohio State Board of Pharmacy Report of Investi­gation, Statement of Dr. James Gesler signed and notarized on May 4, 1998.

(16)    Exhibit 11--Copies of two pages of patient profile records of Richard Shimmel dated from January 18, 1996, through February 1, 1998; and, copies of the following prescriptions 380208, 379409, 382985, 382842, 379962, 379665, 384247, 380207, 382938, 383018, 378928, 379591, 379636, and 378650.

(17)    Exhibit 12--Three-page copy of Ohio State Board of Pharmacy Report of Investi­gation, Case No. 98-1192, Statement of Richard Shimmel, signed and notarized on November 15, 1999.

(18)    Exhibit 13--Copies of five pages of patient profile records of Robert Swiger dated from January 11, 1996, through March 23, 1998.

(19)    Exhibit 14--Copy of five spreadsheets regarding Robert D. Swiger, Case No. 98-1429, dated October 22, 1998.

(20)    Exhibit 15--Copy of two-page Ohio State Board of Pharmacy Report of Investigation, Case No. 98-1192, by Agent David Gallagher dated April 8, 1998.

(21)    Exhibit 16--Copies of twenty-seven Accountability Statements of Mikes Rexall Pharmacy, Terminal Distributor No. 02-0123650, dated for the audit period of April 30, 1996, through March 30, 1998, dated January 10, 1999, for the fol­lowing drugs: Ultram 50mg; Soma-Carisoprodol; Oxycontin 40mg; Oxycontin 20mg; Oxycontin 10mg; Tylox and Roxilox 5/500; Percodan and Oxycodone/­APAP; Percocet, Roxicet, and Oxycodone /APAP; Valium 10mg (Diazepam); Valium 5mg (Diazepam); Valium 2mg (Diazepam); Ativan 2mg (Lorazepam); Ativan 1mg (Lorazepam); Ativan .5mg (Lorazepam); Xanax 1mg (Alprazolam); Xanax 0.5mg (Alprazolam); Xanax 0.25mg (Alprazolam); Lorcet 10/650 (Hydro­codone Bitartrate); Lorcet Plus 7.5/650 (Hydro­codone Bitartrate/APAP); Lortab 7.5/500 (Hydrocodone Bitartrate); Vicodin ES 7.5/700 (Hydrocodone Bitartrate); MS Contin 15mg (Morphine Sulfate); MS Contin 30mg (Morphine Sulfate); Ritalin 10mg (Methylphenidate); Ritalin SR 20mg (Methyl­phenidate); Vicodin and Lortab 5/500 (Hydrocodone Bitartrate) and Darvocet N/100 (Propoxyphene Napsylate).

(22)    Exhibit 17--Copies of eighteen prescriptions numbered as follows: 382955, 381877, 381876, 384889, 378826, 379185, 385222, 383877, 384255, 381870, 380578, 373717, 376979, 378129, 378864, 379961, 38 992, and 382349.

(23)    Exhibit 18--Copies of eleven pages of Lathem family profiles: Charles, Deidra, and Sequoia dated from January 4, 1996, through March 23, 1998.

(24)    Exhibit 19--Copies of nineteen prescriptions numbered as follows: 382290, 379322, 379119, 383711, 384377, 384884, 384885, 383710, 383890, 384535, 381047, 381869, 376653, 375422, 378397, 378822, 378543, 378823, and 379120.

(25)    Exhibit 20--Copy of thirty-four-page Ohio State Board of Pharmacy Report of Investigation, Case No. 98-1192, Statement of Nick Strovilas, R.Ph. signed and notarized December 6, 1999.

(26)    Exhibit 21--Copy of nine-page Ohio State Board of Pharmacy Report of Investigation, Case No. 98-1192, Statement of Crist Strovilas, M.D. signed and notarized on December 6, 1999.

(27)    Exhibit 22--Copy of eleven-page Ohio State Board of Pharmacy Report of Investigation, Case No. 98-1192, Statement of Robert Swiger, Sr. signed and notarized on December 22, 1999.

(28)    Exhibit 23--Copy of two-page statement of Thomas Harper, M.D. signed and notarized on January 10, 2000, with the following attachments: copy of four pages of medical records of Robert Swiger dated from November 5, 1999, through January 10, 2000, and copy of patient profile for the family of Robert Swiger: Robert, Lisa, Kathryn and Robert Jr. dated from October 4, 1999, through December 28, 1999.

(29)    Exhibit 24--Copy of Dangerous Drug Distributor Inspection Report of Mike’s Pharmacy, Terminal Distributor No. 02-0123650, dated January 11, 2000, with attached copy of blank Mike’s Pharmacy prescription label, and prescription vial No. 390923.

(30)    Exhibit 25--Copy of seven-page, nineteen-count Indictment, in the Jefferson County Court of Common Pleas, State of Ohio vs. Michael Popovich, Case No. 00-CR-16, dated February 2, 2000.

 

         Respondent's Exhibits:

 

(1)      None

 

FINDINGS OF FACT

 

After having heard the testimony, observed the demeanor of the witness, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the following to be fact:

 

(1)      On February 10, 2000, Michael Popovich was notified by letter of his right to a hearing, his rights in such hearing, and his right to submit his contentions in writing.

 

(2)      As demonstrated by return receipt of February 12, 2000, Michael Popovich received the letter of February 10, 2000, informing him of the allegations against him, and his rights.

 

(3)      Michael Popovich has not responded in any manner to the letter of February 10, 2000, and has not requested a hearing in this matter.

 

(4)      Records of the State Board of Pharmacy indicate that Michael Popovich was originally licensed in the state of Ohio on November 5, 1957, pursuant to examination.  On February 10, 2000, Michael Popovich’s license to practice pharmacy in the state of Ohio was suspended in accordance with Section 3719.121(B) of the Ohio Revised Code.  Further, during the relevant time periods stated herein, Michael Popovich was the Responsible Pharmacist at Mike’s Rexall Pharmacy in Toronto, Ohio, pursuant to Sections 4729.27 and 4729.55 of the Ohio Revised Code and Rule 4729-5-11 of the Ohio Administra­tive Code.

 

(5)      Michael Popovich did, from on or about January 1, 1996, through June 17, 1997, knowingly obtain, possess, or use a controlled substance in an amount exceeding five times the bulk amount, but not exceeding fifty times the bulk amount when the conduct was not in accordance with Chapters 3719. and 4729. of the Ohio Revised Code, to wit: Michael Popovich advised agents of the Board that, approximately one and one-half years prior to June 17, 1997, he abused Hydrocodone Bitartrate 5/500 at the rate of 5-6 days per week, 2-3 times per day.  Such conduct is in violation of Section 2925.11(A) of the Ohio Revised Code.

 

(6)      Michael Popovich did, on or about November 5, 1999, knowingly sell or offer to sell a controlled substance in an amount exceeding five times the bulk amount, but does not exceed fifty times the bulk amount, when the conduct was not in accordance with Chapters 3719. and 4729. of the Ohio Revised Code, to wit: Michael Popovich sold 70 unit doses of Oxycontin 20mg to a patient pursuant to prescription number 390923 when he knew that the quantity had been changed from 20 unit doses to 70 unit doses.  Such conduct is in violation of Section 2925.03(A) of the Ohio Revised Code.

 

(7)      Michael Popovich did, on or about November 5, 1999, knowingly make or affix a false or forged label to a package or receptacle containing a dangerous drug when the conduct was not in accordance with Chapters 3719. and 4729. of the Ohio Revised Code, to wit: Michael Popovich attached a false label to the vial and dispensed 70 unit doses of Oxycontin 20mg to a patient pursuant to false and forged prescription number 390923.  Such conduct is in violation of Sec­tion 2925.23(D) of the Ohio Revised Code.

 

(8)      Michael Popovich did, on or about November 5, 1999, knowingly make a false statement in a prescription, order, report, or record required by Chapter 3719. or 4729. of the Revised Code, to wit: when dispensing prescription number 390923, Michael Popovich omitted the information in the patient’s profile when it was required to be included therein.  Such conduct is in violation of Section 2925.23(A) of the Ohio Revised Code.

 

(9)      Michael Popovich did, on or about November 5, 1999, knowing that an official proceeding or investigation was in progress or was about to or likely to be instituted, make, present, or use any record, document, or thing, knowing it to be false and with purpose to mislead a public official who was engaged in such proceeding or investigation, with purpose to corrupt the outcome of any such proceeding or investigation, to wit: Michael Popovich dispensed 70 unit doses of Oxycontin 20mg to a patient pursuant to false and forged prescription num­ber 390923 and discarded the original prescription.  Such conduct is in viola­tion of Section 2921.12(A)(2) of the Ohio Revised Code.

 

(10)    Michael Popovich did, from on or about April 30, 1996, through November 30, 1999, being employed by, or associated with, any enterprise and conducted or participated in, directly or indirectly, the affairs of the enterprise through a pattern of corrupt activity or the collection of an unlawful debt when the conduct was not in accordance with Chapters 3719. and 4729. of the Ohio Revised Code, to wit: Michael Popovich engaged in a pattern of corrupt criminal activity by continuously committing felony drug crimes.  Such conduct is in violation of Section 2923.32(A)(1) of the Ohio Revised Code.

 

(11)    Michael Popovich did, from on or about April 30, 1996, through November 30, 1999, knowingly attempt to furnish another a sample drug, to wit: the following drug samples were removed from Mikes Rexall Pharmacy prior to being dis­pensed to patients:

 

         CONTENTS OF EVIDENCE BOX #2:

                                                                Type of           Qty found         Qty noted

         Sample Drug/Strength/Form            container          in the vial         on the vial

            Altace cap                                  mfg. pkg.                191                  192

            Altace cap                                  mfg. pkg.                175                  176

            Amaryl 2mg                                mfg. pkg.                  49                    48

            Amaryl 4mg                                mfg. pkg.                  47                    48

            Capozide 25mg                          mfg. pkg.                266                  270

            Capozide tab                              mfg. pkg.                106                    72

            Corgard                                      mfg. pkg.                  95                  112

            Corzide 5mg tablet                          vial                    305                no  #

            Covera HS tab                                 vial                    100                  180

            Covera HS tab 240mg                 mfg. pkg.                  75                    75

            Diovan 80mg                              mfg. pkg.                107                  108

            Lotensin 10mg                            mfg. pkg.                416                    70

            Lotrel 10/2.5 cap                        mfg. pkg.                  95                 no #

            Monopril 10mg tab                          vial                    126                 no #

            Monopril 10mg tab                     mfg. pkg.                236                  105

            Monopril tablet                            mfg. vial                670                 no #

            Mykrox tablet                                  vial                      60                    60

            Nizoral tablet                                   vial                      34                    20

            Pravachol tab                              mfg. pkg.                  44                      4

            Rynatan tab                                     vial                      66                    88

            Rynatan tab                                     vial                      60                  108

            Rynatuss tab                                   vial                        8                      8

            Serzone tablets                                vial                      27                 no #

            Serzone tablets                           mfg. pkg.                178                  167

                                                                Type of           Qty found         Qty noted

         Sample Drug/Strength/Form            container          in the vial         on the vial

            Suprax 400mg  tab                     mfg. pkg.                  25                 no #

            Suprax 400mg tab                           vial                      36                    36

            Suprax tab                                       vial                      18                    25

            Synthroid tabs                                 vial                      32                 no #

            Synthroid 175mg                        mfg. pkg.                  42                    42

            Tegretol 200mg tab                    mfg. pkg.                  95                      8

            Trandate 200mg tabs (split in half)    vial                      30                 no #

            Vaseretic 10/25 tabs                  mfg. pkg.                113                      4

            Vaseretic 5/12.5 tabs                  mfg. pkg.                111                      4

            Verelan 180mg cap                     mfg. pkg.                105                 no #

            Verelan 360mg caps                        vial                      50                 no #

            Verelan 120mg tab                     mfg. pkg.                  19                    20

            Zocor 40mg tablet                           vial                    113                  112

            Zoloft tab                                   mfg. pkg.                164                  168

 

         CONTENTS OF EVIDENCE BOX #3:

                                                                Type of           Qty found         Qty noted

         Sample Drug/Strength/Form            container          in the vial         on the vial

            Anaprox DS tabs                        mfg. bottle              170                 no #

            Avapro 150mg                                vial                      91                    91

            Coreg 6.25                                      vial                    140                  140

            Duratus G 1200mg                          vial                      25                    50

            Effexor 75mg                                   vial                      12                    12

            Effexor 37.5 tabs                             vial                    120                  120

            Fosamox 10mg tab                         vial                      18                    18

            Fosamox 5mg tab                           vial                      35                    36

            Fumadine tabs                                 vial                      29                    30

            Lodine 500mg tabs                    mfg. bottle                78                  108

            Lotrel 5/20 cap                               vial                      48                    48

            Lotrel 2.5/10                                   vial                      95                    96

            Mavik 1mg tabs                               vial                      97                    91

            Mavik 1mg tabs                               vial                    420                  420

            Microzide 12.5mg caps                    vial                      56                    56

            Microzide 12.5mg caps                    vial                    220                  240

            Nu-Iron tabs                                     vial                      11                    11

            Slow Fe tabs                                   vial                    120                 no #

            Tarka 1mg/240 tab                         vial                      35                    35

            Tarka 2/180 tab                              vial                    105                  105

            Tarka 2/240 tab                              vial                      70                    70

            Tarka 2/240 tab                              vial                      35                    35

            Tarka 4/240                                    vial                      35                    35

            Tarka 4/240                                    vial                      69                    70

            Tiazac 360mg caps                         vial                      34                    35

            Tritec 400mg                                   vial                    139                  140

            Valtrex 500mg tab                          vial                      65                    61

 

         CONTENTS OF EVIDENCE BOX #4:

                                                                Type of           Qty found         Qty noted

         Sample Drug/Strength/Form            container          in the vial         on the vial

            Anatuss LA tabs                         mfg. bottle              232                  221

            Covera HS 180mg tabs              mfg. bottle              174                  175

            Duratuss 1200mg                      mfg. bottle                50                    54

            Lodine 500mg                           mfg. bottle              252                  230

            Phrenilin 50mg                           mfg. bottle              166                  168

            Phrenilin Forte 50mg caps                vial                      54                    54

            Precose 50mg                            mfg. bottle              374                  470

                                                                Type of           Qty found         Qty noted

         Sample Drug/Strength/Form            container          in the vial         on the vial

            Sedapap 50/650                       mfg. bottle                99                  236

            Semprex caps                            mfg. bottle              239                  348

            Valtrex 500mg                           mfg. bottle              156                  156

            Zephrex LA tabs                         mfg. bottle                76                    96

            Zyflo 600mg                              mfg. bottle                95                    96

 

         CONTENTS OF EVIDENCE BOX #7:

                                                                Type of           Qty found         Qty noted

         Sample Drug/Strength/Form            container          in the vial         on the vial

            Cardizem 240mg CD tabs                vial                      56                 no #

            EC -Naprosyn 500mg tab                 vial                      59                 no #

            EC-Naprosyn 375mg tabs                 vial                      69                    70

            Lorabid 200mg caps                        vial                        6                    72

            Lorabid 200mg caps                        vial                      60                    60

            Lorabid 400mg  caps                       vial                      20                    20

            Lotensin 10mg tabs                     mfg. vial                180                  100

            Lotrel 5/10                                      vial                      45                    48

              (sample handwritten on the label)

            Paxil 30mg tabs                               vial                      30                 no #

            Precose 50mg tabs                      mfg. vial                204                  100

            Prilosec 10mg caps                          vial                      44                    70

            Prozac 30mg caps                           vial                      52                 no #

            Prozac 20mg caps                       mfg. vial                129                  100

            Prozac 20mg caps                       mfg. vial                  79                    30

            Prozac 20mg caps                       mfg. vial                143                  100

            Prozac 30mg caps                           vial                      80                 no #

            Seldane 60mg tabs                      mfg. vial                157                  100

            Syn-Rx DM tabs (two vials banded vials / pkt                 78                       

               together with sample packet)

 

         CONTENTS OF EVIDENCE BOX #9:

                                                                Type of           Qty found         Qty noted

         Sample Drug/Strength/Form            container          in the vial         on the vial

            Arthrotec 75mg tabs                       vial                      11                    14

               (with patient name John Smuda)

            Cefzil 500mg                                   vial                      14                    24

            Cipro 750 tabs                                vial                        3                 no #

            Cipro Cystitis 100mg tabs                vial                      18                    18

            Cystospaz .375 caps                  sample vial                21                    12

            Deconsal Sprinkle cap                sample vial                25                      4

            Dulcolax 5mg tab                      sample vial                17                      5

            Famvir 125mg tabs                          vial                    127                    95

            Famvir 250mg tab                           vial                      15                    15

            Generic Elavil 100mg                        vial                    183                 no #

            Hemaspan tab                                 vial                      24                    24

            Lamisil Tabs                                     vial                      12                    12

            Levaquin 250mg tab                        vial                      14                    12

            Maxaquin  400mg tabs                    vial                        8                      8

            Mevacor 10mg                                vial                      96                    96

            Naprosyn  375mg tabs                    vial                        5                    20

            Normodyne  100mg tabs             mfg. vial                194                  100

            Pink Gray capsule (Unknown)             vial                      44                 no #

            Posicor 100mg tab                          vial                      28                    28

            Posicor 50mg tab                            vial                      28                 no #

            Posicor 50mg tab                            vial                    139                  140

            Premphase .625 mg/5 mg                vial                    140                  140

            Prozac 10 mg caps                          vial                        7                 no #

                                                                Type of           Qty found         Qty noted

         Sample Drug/Strength/Form            container          in the vial         on the vial

            Seldane tablets   (National Rx vial  patient vial                38                    60

               with label for William Apesos)

            Synthroid 112mg tabs                     vial                      42                    42

            Synthroid tab                                   vial                      42                    42

            Theo  400mg                                   vial                      18                 no #

            Tolectin 600mg                         sample vial                42                      6

            Toprol XL 200mg tab                 sample vial                26                      7

            Uni-Dur 400mg tabs                   sample vial                21                      7

               (in a 600mg sample bottle)

            Uro-Mag caps                            sample vial              119                    60

            Ziac 10 / 6.25mg tabs                     vial                        5                 no #

            Zocor 40mg                                    vial                      86                  136

            Zocor 5mg tabs                         sample vial                  8                      4

            Zoloft 50mg tabs                         mfg vial                 301                  100

            Zoloft 50mg tabs                             vial                    278                 no #

            Zovirax  400mg                               vial                      10                    10

 

         CONTENTS OF EVIDENCE BOX #11:

                                                                Type of           Qty found         Qty noted

         Sample Drug/Strength/Form            container          in the vial         on the vial

            Axocet                                        mfg. vial                  66                    72

            Covera HS 240mg tab                  mfg. vial                198                  200

            EC Naprosyn 500mg                     mfg. vial                  90                  160

            Lotrel 2.5mg                                    vial                      48                    48

            Midrin 65/100/325                          vial                      60                 no #

            Naprelan 500mg tabs                   mfg. vial                169                  216

            Pink Tab P/F no label on vial         mfg. vial                269                 no #

            Pink Tab P/F no label on vial         mfg. vial                261                 no #

            Premphase .625                               vial                      42                    42

            Premphase .625                               vial                      42                    42

            Sporonax                                     mfg. vial                  61                 no #

            Sular 20mg                                  mfg. vial                185                  416

            Sular 20mg                                  mfg. vial                151                  252

            Tarka 1/240                                mfg. vial                104                    70

            Theo 24 200mg caps                   mfg. vial                203                  223

            Tiazac 180mg caps                      mfg. vial                247                  379

            Tiazac 300mg caps                      mfg. vial                135                  285

            Trinalin 3.72 tabs                         mfg. vial                668                 no #

            Trinalin 3.72 tabs                         mfg. vial                140                 no #

            Uniphyl 600mg                         Smuckers Jar             298                  298

            Univasc 15mg                                  vial                      29                 no #

               ( pills are split in the bottle )

            Univasc 15mg                                  vial                      32                 no #

               ( pills are split in the bottle )

            Univasc 15mg tabs                      mfg. vial                708                  770

            Zyflo 600mg                                mfg. vial                  64                    64

 

         Such conduct is in violation of Section 2923.02 of the Ohio Revised Code as it relates to Section 2925.36 of the Ohio Revised Code.

 

(12)    Michael Popovich did, on or about April 30, 1996, through November 5, 1999, adulterate, mutilate, destroy, obliterate, or remove the whole or any part of the labeling of a drug, while the article was held for sale, resulting in the article being misbranded, to wit: agents of the Board discovered that the word “sample” was crudely scraped off medications in an attempt to alter their distribution appearance prior to sale; the following is implicative of Michael Popovich’s conduct:

 

                                        Drug                                        Quantity

                        Monopril 10mg                                             24

                        Monopril 10mg                                             94

                        Soma Compound 200/325                            80

 

         Such conduct is in violation of Section 3715.52(A) of the Ohio Revised Code.

 

CONCLUSIONS OF LAW

 

(1)      Upon consideration of the record as a whole, the State Board of Pharmacy concludes that paragraphs (5) through (11) of the Findings of Fact constitute being guilty of a felony as provided in Division (A)(1) of Section 4729.16 of the Ohio Revised Code.

 

(2)      Upon consideration of the record as a whole, the State Board of Pharmacy concludes that paragraphs (5) through (12) of the Findings of Fact constitute being guilty of dishonesty and unprofessional conduct in the practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.

 

(3)      Upon consideration of the record as a whole, the State Board of Pharmacy concludes that paragraph (5) of the Findings of Fact constitutes being addicted to or abusing liquor or drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy as provided in Division (A)(3) of Section 4729.16 of the Ohio Revised Code.

 

(4)      Upon consideration of the record as a whole, the State Board of Pharmacy concludes that paragraphs (5) through (8), (11), and (12) of the Findings of Fact constitute being guilty of willfully violating, conspiring to violate, attempting to violate, or aiding and abetting the violation of provisions of Sections 3715.52 to 3715.72 or Chapter 2925. or 3719. of the Revised Code as provided in Division (A)(5) of Section 4729.16 of the Ohio Revised Code.

 

ACTION OF THE BOARD

 

Pursuant to Section 3719.121 of the Ohio Revised Code, the State Board of Pharmacy hereby removes the Summary Suspension Order issued to Michael Popovich.

 

Pursuant to Section 4729.16 of the Ohio Revised Code, the State Board of Pharmacy takes the following actions in the matter of Michael Popovich:

 

(A)     On the basis of the Findings of Fact and paragraph (1) of the Conclusions of Law set forth above, the State Board of Pharmacy hereby revokes the pharma­cist identification card, No. 03-1-06619, held by Michael Popovich effective as of the date of the mailing of this Order.

 

(B)      On the basis of the Findings of Fact and paragraph (2) of the Conclusions of Law set forth above, the State Board of Pharmacy hereby revokes the pharma­cist identification card, No. 03-1-06619, held by Michael Popovich effective as of the date of the mailing of this Order.

 

(C)      On the basis of the Findings of Fact and paragraph (3) of the Conclusions of Law set forth above, the State Board of Pharmacy hereby revokes the pharma­cist identification card, No. 03-1-06619, held by Michael Popovich effective as of the date of the mailing of this Order.

 

(D)     On the basis of the Findings of Fact and paragraph (4) of the Conclusions of Law set forth above, the State Board of Pharmacy hereby revokes the pharma­cist identification card, No. 03-1-06619, held by Michael Popovich effective as of the date of the mailing of this Order.

 

THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY.

MOTION CARRIED.

SO ORDERED.

 

                     The motion was seconded by Ms. Eastman and approved by the Board (Aye-6/Nay-0/Abstain-2[Adelman, Littlejohn]).

  4:20 p.m.

RES. 2000-151  The Board then discussed a proposal to use bar code technology in the dispensing pro­cedures from Omnicare.  After discussion, Ms. Eastman moved that the Board approve the procedure and the use of the bar code technology as outlined as long as the proce­dure used also includes a method of meeting the requirements for positive identification and the use of an exception report for error tracking.  The motion was seconded by Mr. Giacalone and approved (Aye-7/Nay-0/Abstain-1[Neuber]).

 

                     Ms. Abele reported that the Nursing Formulary Committee had not met since the last Board meeting, but was to meet next week.

 

                     Mr. Benedict gave a report on the activities of the Medical Board’s Prescribing Com­mittee.

  4:45 p.m.

                     The Board meeting recessed until Wednesday, April 5, 2000.

 

 

wednESDAY, april 5, 2000

 

  8:40 a.m.      ROLL CALL

 

                     The State Board of Pharmacy convened in Room 1948, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio with the following members present:

 

                           Robert B. Cavendish, R.Ph. (President); Diane C. Adelman, R.Ph. (Vice-President); Ann D. Abele, R.Ph.; Suzanne R. Eastman, R.Ph.; Robert P. Giacalone, R.Ph.; Lawrence J. Kost, R.Ph.; Suzanne L. Neuber, R.Ph.; and Nicholas R. Repke, Public Member.

  8:57 a.m.

                     After discussion of the proposed Minutes from the March 6, 7, 2000 meeting, Ms. Abele moved that they be approved as amended.  The motion was seconded by Ms. Eastman and approved (Aye-6/Nay-0/Abstain-1[Neuber]).

  9:15 a.m.

                     The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Frank Lancz, R.Ph., Toledo, Ohio.

11:00 a.m.

                     The hearing was recessed for lunch.

12:45 p.m.

                     The hearing in the matter of Frank Lancz, R.Ph. resumed.

  1:37 p.m.

                     The hearing concluded and the record was closed.  The Board took a brief recess.

  1:45 p.m.

                     Mr. Repke moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code.  The motion was seconded by Mr. Kost and a roll call vote was conducted by President Cavendish as follows: Abele-Yes, Adelman-Yes, Eastman-Yes, Giacalone-Yes, Kost-Yes, Neuber-Yes, and Repke-Yes.

  2:07 p.m.

RES. 2000-152  The Executive Session ended and the Board meeting resumed in Public Session.  Ms. Eastman moved that the Board adopt the following Order in the matter of Frank Lancz, R.Ph.:

 

ORDER OF THE STATE BOARD OF PHARMACY

(Docket No. D-000121-041)

 

In The Matter Of:

 

FRANK LANCZ, R.Ph.

629 Regina Parkway

Toledo, Ohio  43612

(R.Ph. No. 03-3-12072)

 

INTRODUCTION

 

THE MATTER OF FRANK LANCZ CAME TO HEARING ON APRIL 5, 2000, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: ROBERT B. CAVENDISH, R.Ph. (presiding); ANN D. ABELE, R.Ph.; DIANE C. ADELMAN, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; LAWRENCE J. KOST, R.Ph.; SUZANNE L. NEUBER, R.Ph.; AND NICHOLAS R. REPKE, PUBLIC MEMBER.

 

FRANK LANCZ WAS REPRESENTED BY ROBERT D. NOBLE, AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.

 

SUMMARY OF EVIDENCE

 

(A)     Testimony

 

         State's Witnesses:

 

(1)      Dale R. Fritz, Ohio State Board of Pharmacy

 

         Respondent's Witnesses:

 

(1)      Frank Lancz, Respondent

 

(B)      Exhibits

 

         State's Exhibits:

 

(1)      Exhibit 1--Copy of ten-page Notice of Opportunity for Hearing dated January 21, 2000.

(2)      Exhibit 1A--Letter from Robert D. Noble dated January 12, 2000.

(3)      Exhibit 1B--Hearing Request letter dated January 24, 2000.

(4)      Exhibit 1C--Copy of Hearing Schedule letter dated  January 28, 2000.

(5)      Exhibit 1D--Copy of Pharmacist File Front Sheet of Frank Lancz showing original date of registration as March 29, 1977; and two-page copy of Renewal Appli­cation For Pharmacist License, No. 03-3-12072, of Frank Lancz dated July 28, 1999.

(6)      Exhibit 2--Prescription order for Ronald Pawlowicz dated June 13, 1997, with attached prescription tag no. 4062183 dated June 13, 1997.

(7)      Exhibit 3--Handwritten telephone prescription order for Ron Pawlowicz dated August 11, 1997, with attached prescription tag no. 4063403 dated August 11, 1997.

(8)      Exhibit 4--Handwritten telephone prescription order for Ronald Pawlowicz, not dated, with attached prescription tag no. 4063510 dated August 18, 1997.

(9)      Exhibit 5--Handwritten telephone prescription order for R. Pawlowicz, not dated, with attached prescription tag no. 6411689 dated February 19, 1998.

(10)    Exhibit 6--Handwritten telephone prescription order for Ron Pawlowicz dated April 8, 1998, with attached prescription tag no. 6416142 dated April 8, 1998.

(11)    Exhibit 7--Handwritten telephone prescription order for Ron Pawlowicz dated November 27, 1998, with attached prescription tag no. 4069843 dated Novem­ber 27, 1998.

(12)    Exhibit 8--Handwritten telephone prescription order for Ron Pawlowicz dated December 29, 1998, with attached prescription tag no. 4070249 dated December 29, 1998.

(13)    Exhibit 9--Copy of two-page Cub Pharmacy #619 Medical Expenses report, dated November 23, 1999, of Ronald Pawlowicz for the period from July 28, 1997, to November 23, 1999 showing R.Ph. Mark Everett; and copy of Cub Pharmacy #619 Medical Expenses report, not dated, of Ronald Pawlowicz for the period to July 19, 1999, with no from date, showing R.Ph. Frank Lancz.

(14)    Exhibit 10--Two-page handwritten statement of Frank Lancz dated July 20, 1999.

(15)    Exhibit 11--Handwritten telephone prescription order for Ron Pawlowicz dated March 12, 1999, with attached prescription tag no. 4071296 dated March 12, 1999.

(16)    Exhibit 12--Handwritten telephone prescription order for R. Pawlowicz, not dated, with attached prescription tag no. 6396585 dated September 17, 1997.

(17)    Exhibit 13--Handwritten telephone prescription order for an unknown patient dated October 29, 1999, with attached prescription tag no. 6400640 dated October 29, 1997 for Ronald Pawlowicz.

(18)    Exhibit 14--Handwritten telephone prescription order for Ron Pawlowicz dated December 4, 1998, with attached prescription tag no. 6436445 dated December 4, 1998.

(19)    Exhibit 15--Handwritten telephone prescription order for Ron Pawlowicz dated February 4, 1999, with attached prescription tag no. 6441732 dated February 4, 1999, and attached prescription tag no. 6441733 dated February 4, 1999.

(20)    Exhibit 16--Handwritten telephone prescription order for R. Pawlowicz, not dated, with attached prescription tag no. 6455509 dated July 18, 1999.

(21)    Exhibit 17--Handwritten prescription order for Ron Pawlowicz dated November 6, 1997, with attached prescription tag no. 4064669 dated November 6, 1997.

(22)    Exhibit 18--Handwritten prescription order for Ronald Pawlowicz dated December 21, 1997, with attached prescription tag no. 4065298 dated December 22, 1997.

(23)    Exhibit 19--Handwritten statement of James A. Clouse dated July 26, 1999.

(24)    Exhibit 20--Handwritten prescription order for James Clouse, not dated, with attached prescription tag no. 2010874 dated March 30, 1999.

(25)    Exhibit 21--Handwritten prescription order for James Clouse dated March 29, 1999, with attached prescription tag no. 2010875 dated March 30, 1999.

(26)    Exhibit 22--Handwritten prescription order for James Clouse dated March 29, 1999, with attached prescription tag no. 2010876 dated March 30, 1999.

(27)    Exhibit 23--Handwritten prescription order for James Clouse dated April 10, 1999, with attached prescription tag no. 2010904 dated April 11, 1999.

(28)    Exhibit 24--Handwritten prescription order for James Clouse dated April 10, 1999, with attached prescription tag no. 2010905 dated April 11, 1999.

(29)    Exhibit 25--Handwritten prescription order for James Clouse dated April 16, 1999, with attached prescription tag no. 2010932 dated April 20, 1999.

(30)    Exhibit 26--Handwritten prescription order for James Clouse dated April 19, 1999, with attached prescription tag no. 2010933 dated April 20, 1999.

(31)    Exhibit 27--Handwritten prescription order for James Clouse dated April 30, 1999, with attached prescription tag no. 2010980 dated May 3, 1999.

(32)    Exhibit 28--Handwritten prescription order for James Clouse dated May 14, 1999, with attached prescription tag no. 2011018 dated May 16, 1999.

(33)    Exhibit 29--Handwritten prescription order for James Clouse dated July 3, 1999, with attached prescription tag no. 2011147 dated July 5, 1999.

(34)    Exhibit 30--Copy of Cub Pharmacy #619 Medical Expenses report, dated Novem­ber 23, 1999, of James Clouse for the period from March 30, 1999, to Novem­ber 23, 1999, showing R.Ph. Mark Everett.

(35)    Exhibit 31--Consultation/Third Party Signature Log dated July 6, 1999.

(36)    Exhibit 32--Consultation/Third Party Signature Log dated April 2, 1999.

(37)    Exhibit 33--Handwritten prescription order for Ronald Pawlowicz dated Decem­ber 21, 1997, with attached prescription tag no. 4065299 dated December 22, 1997.

(38)    Exhibit 34--Three vials of Nalbuphine 20mg/ml.

(39)    Exhibit 35--Three vials of Benadryl 50mg/ml.

(40)    Exhibit 36--One box of Maxalt-mlt 10mg.

(41)    Exhibit 37--Twelve tablets of Mavik 4mg.

(42)    Exhibit 38--Eight Librax capsules.

(43)    Exhibit 39--One bottle of Hurricane Topical Gel.

(44)    Exhibit 40--One bottle of Nystatin suspension.

(45)    Exhibit 41--Seventeen unused hypodermics.

(46)    Exhibit 42--Numerous used hypodermics.

(47)    Exhibit 43--Copy of St. Charles Hospital Patient Incident Report dated January 3, 1995.

(48)    Exhibit 44--Copy of St. Charles Hospital Discussion Summary dated January 5, 1995.

(49)    Exhibit 45--Ten-page copy of eighteen-count Indictment in the Lucas County Common Pleas Court, Case No. CR99-2458, State of Ohio vs. Ronald Pawlowicz, Frank Lancz and Connie Lancz, dated September 8, 1999.

 

         Respondent's Exhibits:

 

(1)      None

 

FINDINGS OF FACT

 

After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the following to be fact:

 

(1)      Records of the State Board of Pharmacy indicate that Frank Lancz was originally licensed in the state of Ohio on March 29, 1977, pursuant to examination, and is currently licensed to practice pharmacy in the state of Ohio.

 

(2)      Frank Lancz did, on or about June 13, 1997, through March 1, 1999, intention­ally make, utter, or sell, or knowingly possess a false or forged prescription, to wit: Frank Lancz created the following prescriptions for Patient #1, purportedly written by Dr. Philip Lepkowski:

 

              Rx Number              Date                                   Drug/Strength                               Quantity

                4062519            06/13/97            Vicodin ES                                                              90

                4062519            08/08/97            Vicodin ES                                                              90

                4063403            08/11/97            Lorazepam 0.5mg                                                  30

                4063510            08/22/97            Hydrocodone 5mg/APAP 500mg                        10

                4062519            09/05/97            Vicodin ES                                                              90

                4062519            10/10/97            Vicodin ES                                                              90

                6402627            11/18/97            Diphenhydramine 50mg/ml  (10ml inj)                 3

                6411689            02/19/98            Diphenhydramine 50mg/ml  (10ml inj)                 3

                6411689            03/09/98            Diphenhydramine 50mg/ml  (10ml inj)                 3

                6411689            03/20/98            Diphenhydramine 50mg/ml  (10ml inj)                 3

                6411689            04/08/98            Diphenhydramine 50mg/ml  (10ml inj)                 3

                6416142            04/08/98            Viagra 100mg                                                         30

              Rx Number              Date                                   Drug/Strength                               Quantity

                6411689            05/10/98            Diphenhydramine 50mg/ml  (10ml inj)                 3

                6411689            05/22/98            Diphenhydramine 50mg/ml  (10ml inj)                 3

                4069843            11/27/98            Hydrocodone 7.5mg/APAP 750mg                    30

                4070249            12/29/98            Vicodin ES                                                              60

                4070249            01/30/99            Vicodin ES                                                              60

                4070249            02/15/99            Vicodin ES                                                              60

                4070249            03/01/99            Vicodin ES                                                              60

 

         Such conduct is in violation of Section 2925.23(B) of the Ohio Revised Code.

 

(3)      Frank Lancz did, on or about March 12, 1999, through June 24, 1999, inten­tionally make, utter, or sell, or knowingly possess a false or forged prescription, to wit: Frank Lancz created the following prescriptions for Patient #1 purport­edly written by Dr. Radecki:

 

                      Rx Number                      Date                       Drug/Strength                   Quantity

                        4071295                    03/12/99                      Lorcet                                  90

                        4071296                    03/12/99                      Stadol NS                              3ml

                        4071296                    03/23/99                      Stadol NS                              3ml

                        4071295                    04/11/99                      Lorcet                                  90

                        4071295                    05/03/99                      Lorcet                                  90

                        4071295                    06/01/99                      Lorcet                                  90

                        4071295                    06/15/99                      Lorcet                                  90

                        4071295                    06/24/99                      Lorcet                                  90

 

         Such conduct is in violation of Section 2925.23(B) of the Ohio Revised Code.

 

(4)      Frank Lancz did, on or about August 13, 1997, through July 18, 1999, inten­tionally make, utter, or sell, or knowingly possess a false or forged prescription, to wit: Frank Lancz created the following prescriptions for Patient #1 purport­edly written by a physician at St. Luke’s Hospital:

 

              Rx Number              Date                                   Drug/Strength                               Quantity

                6393349            08/13/97            Nalbuphine Injection 20mg/ml                         20ml

                6393349            08/28/97            Nalbuphine Injection 20mg/ml                         20ml

                6393349            09/08/97            Nalbuphine Injection 20mg/ml                         20ml

                6396585            09/18/97            Nalbuphine Injection 20mg/ml                         30ml

                6396585            10/02/97            Nalbuphine Injection 20mg/ml                         30ml

                6396585            10/16/97            Nalbuphine Injection 20mg/ml                         30ml

                6400640            10/29/97            Nalbuphine Injection 20mg/ml                         30ml

                6400640            11/10/97            Nalbuphine Injection 20mg/ml                         30ml

                6400640            11/20/97            Nalbuphine Injection 20mg/ml                         30ml

                6400640            12/12/97            Nalbuphine Injection 20mg/ml                         30ml

                6400640            01/06/98            Nalbuphine Injection 20mg/ml                         30ml

                6436445            12/04/98            Nalbuphine Injection 20mg/ml                         10ml

                6441733            02/04/99            Diphenhydramine 50mg/ml  (10ml inj)               3

                6441732            02/04/99            Nalbuphine Injection 20mg/ml                         30ml

                6441733            02/26/99            Diphenhydramine 50mg/ml  (10ml inj)               3

                6441732            02/26/99            Nalbuphine Injection 20mg/ml                         30ml

                6441733            03/11/99            Diphenhydramine 50mg/ml  (10ml inj)               3

                6441732            03/22/99            Nubain Injection 20mg/ml                                 30ml

                6441733            03/30/99            Diphenhydramine 50mg/ml  (10ml inj)               3

                6441732            04/02/99            Nalbuphine Injection 20mg/ml                         30ml

                6441732            06/04/99            Nalbuphine Injection 20mg/ml                         30ml

                6441732            06/21/99            Nalbuphine Injection 20mg/ml                         30ml

                6441732            07/01/99            Nalbuphine Injection 20mg/ml                         30ml

                6455509            07/18/99            Nalbuphine Injection 20mg/ml                         30ml

 

         Such conduct is in violation of Section 2925.23(B) of the Ohio Revised Code.

 

(5)      Frank Lancz did, on or about November 6, 1997, through January 8, 1999, intentionally make, utter, or sell, or knowingly possess a false or forged pre­scription, to wit: Frank Lancz created the following prescriptions for Patient #1 purportedly written by a physician at Toledo Hospital:

              Rx Number              Date                                   Drug/Strength                               Quantity

                4064669            11/06/97            Vicodin ES                                                            60

                4064669            11/28/97            Hydrocodone 7.5mg/APAP 750mg                  60

                4065299            12/22/97            Dihistine DH                                                       240ml

                4065298            12/22/97            Vicodin ES                                                            40

                4065298            01/08/98            Hydrocodone 7.5mg/APAP 750mg                  40

 

         Such conduct is in violation of Section 2925.23(B) of the Ohio Revised Code.

 

(6)      Frank Lancz did, on or about March 30, 1999, through July 5, 1999, inten­tionally make, utter, or sell, or knowingly possess a false or forged prescription, to wit: Frank Lancz created the following schedule II controlled substance prescriptions for Patient #2 purportedly written by Dr. Harry Snyder:

 

              Rx Number              Date                                   Drug/Strength                               Quantity

                2010874            03/30/99            Endocet 5-325mg tablets                                  20

                2010875            04/02/99            Dilaudid 2mg tablets                                           60

                2010876            04/02/99            Morphine Sulfate 10mg tablets                        60

                2010904            04/11/99            Morphine Sulfate 10mg tablets                        40

                2010905            04/11/99            Morphine Sulfate 30mg tablets                        60

                2010932            04/20/99            Morphine Sulfate 30mg tablets                        60

                2010933            04/20/99            Dilaudid 2mg tablets                                           40

                2010980            05/03/99            Morphine Sulfate 30mg tablets                      120

                2011018            05/17/99            Morphine Sulfate 30mg tablets                      120

                2011147            07/05/99            Endodan tablets                                                  40

 

         Such conduct is in violation of Section 2925.23(B) of the Ohio Revised Code.

 

(7)      Frank Lancz did, from June 13, 1997, through March 1, 1999, sell a controlled substance in an amount exceeding five times the bulk amount, but in an amount less than fifty times that amount, when the conduct was not in accor­dance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: throughout this time period Frank Lancz sold 830 unit doses of Hydrocodone 7.5mg/APAP 750mg, a schedule III controlled substance, to Patient #1 without a legitimate medical purpose:

 

              Rx Number              Date                                   Drug/Strength                               Quantity

                4062519            06/13/97            Vicodin ES                                                            90

                4062519            08/08/97            Vicodin ES                                                            90

                4062519            09/05/97            Vicodin ES                                                            90

                4062519            10/10/97            Vicodin ES                                                            90

                4064669            11/06/97            Vicodin ES                                                            60

                4064669            11/28/97            Hydrocodone 7.5mg/APAP 750mg                  60

                4065298            12/22/97            Vicodin ES                                                            40

                4069843            11/27/98            Hydrocodone 7.5mg/APAP 750mg                  30

                4070249            12/29/98            Vicodin ES                                                            60

                4065298            01/08/99            Hydrocodone 7.5mg/APAP 750mg                  40

                4070249            01/30/99            Vicodin ES                                                            60

                4070249            02/15/99            Vicodin ES                                                            60

                4070249            03/01/99            Vicodin ES                                                            60

 

         Such conduct is in violation of Section 2925.03(A) of the Ohio Revised Code.

 

(8)      Frank Lancz did, on March 12, 1999, and again on March 23, 1999, sell a con­trolled substance in an amount less than the bulk amount when the conduct was not in accordance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: on each occasion Frank Lancz sold 3ml of Stadol NS 10mg/ml, a schedule IV controlled substance, to Patient #1 without a legitimate medical purpose pursuant to prescription number 4071296.  Such conduct is in violation of Section 2925.03(A) of the Ohio Revised Code.

 

(9)      Frank Lancz did, from March 12, 1999, through June 24, 1999, sell a controlled substance in an amount exceeding five times the bulk amount, but in an amount less than fifty times that amount, when the conduct was not in accor­dance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: throughout this time period Frank Lancz sold 540 unit doses of Lorcet, a schedule IV controlled substance, to Patient #1 without a legitimate medical purpose:

 

                      Rx Number                      Date                       Drug/Strength                   Quantity

                        4071295                    03/12/99                        Lorcet                                90

                        4071295                    04/11/99                        Lorcet                                90

                        4071295                    05/03/99                        Lorcet                                90

                        4071295                    06/01/99                        Lorcet                                90

                        4071295                    06/15/99                        Lorcet                                90

                        4071295                    06/24/99                        Lorcet                                90

 

         Such conduct is in violation of Section 2925.03(A) of the Ohio Revised Code.

 

(10)    Frank Lancz did, on or about March 30, 1999, sell a controlled substance in an amount less than the bulk amount when the conduct was not in accordance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Frank Lancz sold 20 unit doses of Endocet 5-325mg, a schedule II controlled sub­stance, to Patient #2 without a legitimate medical purpose pursuant to prescrip­tion number 2010874.  Such conduct is in violation of Section 2925.03(A) of the Ohio Revised Code.

 

(11)    Frank Lancz did, on or about April 2, 1999, through July 5, 1999, sell a con­trolled substance in an amount exceeding the bulk amount, but in an amount less than five times that amount, when the conduct was not in accordance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Frank Lancz sold the following schedule II controlled substances to Patient #2 without a legi­timate medical purpose:

 

              Rx Number                      Date                                   Drug/Strength                       Quantity

                2010875                    04/02/99                      Dilaudid 2mg tablets                         60

                2010933                    04/20/99                      Dilaudid 2mg tablets                         40

                2011147                    07/05/99                      Endodan                                              40

 

         Such conduct is in violation of Section 2925.03(A) of the Ohio Revised Code.

 

(12)    Frank Lancz did, on or about April 2, 1999, and again on April 11, 1999, sell
a controlled substance in an amount exceeding the bulk amount, but in an amount less than five times that amount, when the conduct was not in accor­dance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Frank Lancz sold a total of 100 unit doses of Morphine Sulfate 10mg, a schedule II controlled substance, to Patient #2 without a legitimate medical purpose pursuant to the following prescriptions:

 

              Rx Number                  Date                                   Drug/Strength                           Quantity

                2010876                04/02/99                  Morphine Sulfate 10mg tablets              60

                2010904                04/11/99                  Morphine Sulfate 10mg tablets              40

 

         Such conduct is in violation of Section 2925.03(A) of the Ohio Revised Code.

 

(13)    Frank Lancz did, from on or about April 11, 1999, through May 17, 1999, sell
a controlled substance in an amount exceeding five times the bulk amount, but in an amount less than fifty times that amount, when the conduct was not in accordance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code,
to wit: Frank Lancz sold a total of 360 unit doses of Morphine Sulfate 30mg, a schedule II controlled substance, to Patient #2 without a legitimate medical purpose pursuant to the following prescriptions:

 

              Rx Number                  Date                                   Drug/Strength                           Quantity

                2010905                04/11/99                  Morphine Sulfate 30mg tablets              60

                2010932                04/20/99                  Morphine Sulfate 30mg tablets              60

                2010980                05/03/99                  Morphine Sulfate 30mg tablets            120

                2011018                05/17/99                  Morphine Sulfate 30mg tablets            120

 

         Such conduct is in violation of Section 2925.03(A) of the Ohio Revised Code.

 

(14)    Frank Lancz did, on or about the following dates, sell at retail dangerous drugs, to wit: on each occasion Frank Lancz created prescriptions and/or sold danger­ous drugs to Patient #1, without a legitimate medical purpose:

 

              Rx Number              Date                                   Drug/Strength                               Quantity

                4065299            12/22/97            Dihistine DH                                                       240ml

                6402627            11/18/97            Diphenhydramine 50mg/ml  (10ml inj)               3

                6411689            02/19/98            Diphenhydramine 50mg/ml  (10ml inj)               3

                6411689            03/09/98            Diphenhydramine 50mg/ml  (10ml inj)               3

                6411689            03/20/98            Diphenhydramine 50mg/ml  (10ml inj)               3

                6411689            04/08/98            Diphenhydramine 50mg/ml  (10ml inj)               3

                6411689            05/10/98            Diphenhydramine 50mg/ml  (10ml inj)               3

                6411689            05/22/98            Diphenhydramine 50mg/ml  (10ml inj)               3

                6441733            02/04/99            Diphenhydramine 50mg/ml  (10ml inj)               3

                6441733            02/26/99            Diphenhydramine 50mg/ml  (10ml inj)               3

                6441733            03/11/99            Diphenhydramine 50mg/ml  (10ml inj)               3

                6441733            03/30/99            Diphenhydramine 50mg/ml  (10ml inj)               3

                6393349            08/13/97            Nalbuphine Injection 20mg/ml                         20ml

                6393349            08/28/97            Nalbuphine Injection 20mg/ml                         20ml

                6393349            09/08/97            Nalbuphine Injection 20mg/ml                         20ml

                6396585            09/18/97            Nalbuphine Injection 20mg/ml                         30ml

                6396585            10/02/97            Nalbuphine Injection 20mg/ml                         30ml

                6396585            10/16/97            Nalbuphine Injection 20mg/ml                         30ml

                6400640            10/29/97            Nalbuphine Injection 20mg/ml                         30ml

                6400640            11/10/97            Nalbuphine Injection 20mg/ml                         30ml

                6400640            11/20/97            Nalbuphine Injection 20mg/ml                         30ml

                6400640            12/12/97            Nalbuphine Injection 20mg/ml                         30ml

                6400640            01/06/98            Nalbuphine Injection 20mg/ml                         30ml

                6436445            12/04/98            Nalbuphine Injection 20mg/ml                         10ml

                6441732            02/04/99            Nalbuphine Injection 20mg/ml                         30ml

                6441732            02/26/99            Nalbuphine Injection 20mg/ml                         30ml

                6441732            03/22/99            Nubain Injection 20mg/ml                                 30ml

                6441732            04/02/99            Nalbuphine Injection 20mg/ml                         30ml

                6441732            06/04/99            Nalbuphine Injection 20mg/ml                         30ml

                6441732            06/21/99            Nalbuphine Injection 20mg/ml                         30ml

                6441732            07/01/99            Nalbuphine Injection 20mg/ml                         30ml

                6455509            07/18/99            Nalbuphine Injection 20mg/ml                         30ml

                6416142            04/08/98            Viagra 100mg                                                       30

 

         Such conduct is in violation of Section 4729.51(C)(1) of the Ohio Revised Code.

 

(15)    Frank Lancz did, on or about July 20, 1999, knowingly possess a dangerous drug when not in accordance with Chapters 3719. and 4729. of the Ohio Re­vised Code, to wit: Frank Lancz voluntarily turned over the following dangerous drugs, that were in his possession at his residence, to law enforcement:

 

                     Three vials of Nalbuphine 20mg/ml

                     Three vials of Benadryl 50mg/ml

                     One box of Maxalt-mlt 10mg

                     Twelve tablets of Mavik 4mg

                     Eight Librax capsules

                     One bottle of Hurricane Topical Gel

                     One bottle of Nystatin suspension

 

         Such conduct is in violation of Section 4729.51(C)(3) of the Ohio Revised Code.

 

(16)    Frank Lancz did, on or about July 20, 1999, possess for sale hypodermics as drug paraphernalia when not in accordance with Chapters 3719. and 4729. of the Ohio Revised Code, to wit: Frank Lancz voluntarily turned over, to law enforcement, used and unused hypodermics that were in his possession at his residence for purposes of furnishing them to another, but not for a legitimate medical use.  Such conduct is in violation of Section 2925.14(C)(2) of the Ohio Revised Code.

 

(17)    Frank Lancz did, on or about January 3, 1995, sell a misbranded drug, to wit: while working at St. Charles Hospital in Oregon, Ohio, Frank Lancz compounded a solution for the chemotherapy drug 5-fluorouracil.  A pharmacy technician had concerns about the compounding process and questioned Frank Lancz twice about a possible compounding error.  Frank Lancz determined that the solution was correct.  The solution was sent to the nursing unit.  A nurse noticed that the solution was reddish/orange in color; however, after double checking the label, order, and drug book, the drug was administered to the patient who was placed in serious risk.  As a result, Frank Lancz's employment was terminated.  Such conduct is in violation of Section 3715.52 of the Ohio Revised Code.

 

CONCLUSIONS OF LAW

 

(1)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraphs (2) through (16) of the Findings of Fact constitute being guilty of a felony or gross immorality as provided in Division (A)(1) of Section 4729.16 of the Ohio Revised Code.

 

(2)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraphs (2) through (16) of the Findings of Fact constitute being guilty of dishonesty and unprofessional conduct in the practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.

 

(3)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraph (17) of the Findings of Fact constitutes being guilty of unprofessional conduct in the practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.

 

(4)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraphs (2) through (17) of the Findings of Fact constitute being guilty of willfully violating, conspiring to violate, attempting to violate, or aiding and abetting the violation of provisions of Chapters 2925., 3715., and 4729. of the Revised Code as provided in Division (A)(5) of Section 4729.16 of the Ohio Revised Code.

 

ACTION OF THE BOARD

 

Pursuant to Section 4729.16 of the Ohio Revised Code, the State Board of Pharmacy takes the following actions in the matter of Frank Lancz:

 

(A)     On the basis of the Findings of Fact and paragraph (1) of the Conclusions of Law set forth above, the State Board of Pharmacy hereby revokes the pharma­cist identification card, No. 03-3-12072, held by Frank Lancz effective as of the date of the mailing of this Order.

 

(B)      On the basis of the Findings of Fact and paragraphs (2) and (3) of the Conclu­sions of Law set forth above, the State Board of Pharmacy hereby revokes the pharmacist identification card, No. 03-3-12072, held by Frank Lancz effective as of the date of the mailing of this Order.

 

(C)      On the basis of the Findings of Fact and paragraph (4) of the Conclusions of Law set forth above, the State Board of Pharmacy hereby revokes the pharma­cist identification card, No. 03-3-12072, held by Frank Lancz effective as of the date of the mailing of this Order.

 

Division (B) of Section 4729.16 of the Ohio Revised Code requires that any individual whose identification card is revoked, suspended, or refused, shall return the identification card and wall certificate to the office of the State Board of Pharmacy within ten days after receipt of notice of such action.  The wall certificate and identification card should be forwarded by certified mail, return receipt requested.

 

THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY.

MOTION CARRIED.

SO ORDERED.

 

The motion was seconded by Mr. Kost and approved by the Board (Aye-7/Nay-0).

  2:11 p.m.

                     The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Connie Lancz, R.Ph., Toledo, Ohio.

  3:22 p.m.

                     The hearing concluded and the record was closed.  The Board took a brief recess.

  3:30 p.m.

                     Mrs. Adelman moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code.  The motion was seconded by Ms. Abele and a roll call vote was conducted by President Cavendish as follows: Abele-Yes, Adelman-Yes, Eastman-Yes, Giacalone-Yes, Kost-Yes, Neuber-Yes, and Repke-Yes.

  3:55 p.m.

RES. 2000-153  The Executive Session ended and the Board meeting resumed in Public Session.  Mrs. Adelman moved that the Board adopt the following Order in the matter of Connie Lancz, R.Ph.:

 

ORDER OF THE STATE BOARD OF PHARMACY

(Docket No. D-000121-042)

 

In The Matter Of:

 

CONNIE A. LANCZ, R.Ph.

629 Regina Parkway

Toledo, Ohio 43612

(R.Ph. No. 03-2-15206)

 

INTRODUCTION

 

THE MATTER OF CONNIE A. LANCZ CAME TO HEARING ON APRIL 5, 2000, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: ROBERT B. CAVENDISH, R.Ph. (presiding); ANN D. ABELE, R.Ph.; DIANE C. ADELMAN, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; LAWRENCE J. KOST, R.Ph.; SUZANNE L. NEUBER, R.Ph.; AND NICHOLAS R. REPKE, PUBLIC MEMBER.

 

CONNIE A. LANCZ WAS NOT REPRESENTED BY COUNSEL, AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.

 

SUMMARY OF EVIDENCE

 

(A)     Testimony

 

         State's Witnesses:

 

(1)      Dale Fritz, Ohio State Board of Pharmacy

 

         Respondent's Witnesses:

 

(1)      Connie A. Lancz, Respondent

 

(B)      Exhibits

 

         State's Exhibits:

 

(1)      Exhibit 1--Copy of seven-page Notice of Opportunity for Hearing letter dated January 21, 2000.

(2)      Exhibit 1A--Copy of Hearing Request letter dated February 18, 2000.

(3)      Exhibit 1B--Copy of Hearing Schedule letter dated February 18, 2000.

(4)      Exhibit 1C--Copy of Pharmacist File Front Sheet of Connie A. Lancz showing original date of registration as August 10, 1983; and two-page copy of Renewal Application for Pharmacist License, No. 03-2-15206, of Connie A. Lancz dated August 14, 1999.

(5)      Exhibit 2--Copy of Drug Corner Pharmacy Patient Prescription Summary of Lucas Montoya for the period from December 1, 1997, to December 27, 1998, dated December 27, 1998.

(6)      Exhibit 3--Copy of two-page Drug Corner Pharmacy Patient Prescription Sum­mary of Sam Mavis for the period from January 1, 1997, to December 27, 1998, dated December 27, 1998.

(7)      Exhibit 4--Copy of three-page Drug Corner Pharmacy Patient Prescription Sum­mary of Phyllis Baker for the period from January 1, 1997, to December 27, 1998, dated December 27, 1998.

(8)      Exhibit 5--Two-page statement of William M. Aring, R.Ph. dated September 1, 1999, notarized on September 3, 1999.

(9)      Exhibit 6--Ten-page copy of eighteen-count Indictment in the Lucas County Common Pleas Court, State of Ohio vs. Ronald Pawlowicz, Frank Lancz and Connie Lancz, Case No. CR99-2458, dated September 8, 1999.

 

         Respondent's Exhibits:

 

(1)      None

 

FINDINGS OF FACT

 

After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the following to be fact:

 

(1)      Records of the State Board of Pharmacy indicate that Connie A. Lancz was origi­nally licensed in the state of Ohio on August 10, 1983, pursuant to examina­tion, and is currently licensed to practice pharmacy in the state of Ohio.

 

(2)      Connie A. Lancz did, from on or about October 26, 1997, through October 31, 1998, with purpose to deprive, knowingly obtain or exert control over danger­ous drugs, the property of Drug Corner Pharmacy, 1009 W. Sylvania Avenue, Toledo, Ohio, beyond the express or implied consent of the owner and/or by deception, to wit: Connie A. Lancz stole the following controlled substances for personal abuse:

 

                    Rx Number                Date                                 Drug/Strength                     Quantity

                        667287              10/26/97                  Diazepam 5mg/ml                             10ml

                        667288              10/26/97                  Morphine Sulfate 15mg/ml              40ml

                        680947              12/22/97                  Morphine Sulfate 15mg/ml              40ml

                        685554              01/12/98                  Morphine Sulfate 15mg/ml              40ml

                        686827              01/16/98                  Morphine Sulfate 50mg/ml              20ml

                        688369              01/22/98                  Morphine Sulfate 50mg/ml              20ml

                        689966              01/29/98                  Morphine Sulfate 50mg/ml              20ml

                        692957              02/09/98                  Morphine Sulfate 50mg/ml              20ml

                        696487              02/24/98                  Morphine Sulfate 50mg/ml              20ml

                        698676              03/04/98                  Morphine Sulfate 50mg/ml              20ml

                        701786              03/17/98                  Morphine Sulfate 50mg/ml              20ml

                        704891              03/30/98                  Morphine Sulfate 50mg/ml              20ml

                        710205              04/23/98                  Morphine Sulfate 50mg/ml              20ml

                        711914              04/30/98                  Morphine Sulfate 50mg/ml              20ml

                        712555              05/04/98                  Morphine Sulfate 50mg/ml              20ml

                        713575              05/08/98                  Morphine Sulfate 50mg/ml              20ml

                        714223              05/12/98                  Morphine Sulfate 50mg/ml              20ml

                        715820              05/19/98                  Morphine Sulfate 50mg/ml              20ml

                        717842              05/28/98                  Morphine Sulfate 50mg/ml              20ml

                        718076              05/29/98                  Morphine Sulfate 50mg/ml              20ml

                        718593              06/01/98                  Morphine Sulfate 50mg/ml              20ml

                        719128              06/03/98                  Morphine Sulfate 50mg/ml              20ml

                        720359              06/09/98                  Morphine Sulfate 50mg/ml              20ml

                        720593              06/10/98                  Morphine Sulfate 50mg/ml              20ml

                        721502              06/15/98                  Morphine Sulfate 50mg/ml              20ml

                        721877              06/16/98                  Morphine Sulfate 50mg/ml              20ml

                        723597              06/25/98                  Morphine Sulfate 50mg/ml              20ml

                        723598              06/25/98                  Morphine Sulfate 50mg/ml              20ml

                        724424              06/30/98                  Morphine Sulfate 50mg/ml              20ml

                        724425              06/30/98                  Morphine Sulfate 50mg/ml              20ml

                        725658              07/07/98                  Morphine Sulfate 50mg/ml              20ml

                        725945              07/08/98                  Morphine Sulfate 50mg/ml              20ml

                        727268              07/14/98                  Morphine Sulfate 50mg/ml              20ml

                        727542              07/15/98                  Morphine Sulfate 50mg/ml              20ml

                        729036              07/22/98                  Morphine Sulfate 50mg/ml              20ml

                        729233              07/23/98                  Morphine Sulfate 50mg/ml              20ml

                        729805              07/27/98                  Morphine Sulfate 50mg/ml              20ml

                        730029              07/28/98                  Morphine Sulfate 50mg/ml              20ml

                        730501              07/30/98                  Morphine Sulfate 50mg/ml              20ml

                        731282              08/04/98                  Morphine Sulfate 50mg/ml              20ml

                        732593              08/11/98                  Morphine Sulfate 50mg/ml              20ml

                        732855              08/12/98                  Morphine Sulfate 50mg/ml              20ml

                        733336              08/14/98                  Morphine Sulfate 50mg/ml              20ml

                        733617              08/17/98                  Morphine Sulfate 50mg/ml              20ml

                        734128              08/19/98                  Morphine Sulfate 50mg/ml              20ml

                        736668              09/02/98                  Morphine Sulfate 50mg/ml              20ml

                        737084              09/04/98                  Morphine Sulfate 50mg/ml              20ml

                        737827              09/09/98                  Morphine Sulfate 50mg/ml              20ml

                        738267              09/11/98                  Morphine Sulfate 50mg/ml              20ml

                        739169              09/16/98                  Morphine Sulfate 50mg/ml              20ml

                        739590              09/18/98                  Morphine Sulfate 50mg/ml              20ml

                        740000              09/21/98                  Morphine Sulfate 50mg/ml              20ml

                        740433              09/23/98                  Morphine Sulfate 50mg/ml              20ml

                        740869              09/25/98                  Morphine Sulfate 50mg/ml              20ml

                        741068              09/27/98                  Morphine Sulfate 50mg/ml              20ml

                        742314              10/02/98                  Morphine Sulfate 50mg/ml              20ml

                        742313              10/02/98                  Morphine Sulfate 50mg/ml              20ml

                        742781              10/05/98                  Morphine Sulfate 50mg/ml              20ml

                        743576              10/08/98                  Morphine Sulfate 50mg/ml              20ml

                        743795              10/09/98                  Morphine Sulfate 50mg/ml              20ml

                        744885              10/15/98                  Morphine Sulfate 50mg/ml              20ml

                        744891              10/15/98                  Morphine Sulfate 50mg/ml              20ml

                        744896              10/16/98                  Morphine Sulfate 50mg/ml              20ml

                        745447              10/19/98                  Morphine Sulfate 50mg/ml              20ml

                        745474              10/19/98                  Morphine Sulfate 50mg/ml              20ml

                    Rx Number                Date                                 Drug/Strength                     Quantity

                        746135              10/22/98                  Morphine Sulfate 50mg/ml              20ml

                        746751              10/26/98                  Morphine Sulfate 50mg/ml              20ml

                        746812              10/26/98                  Morphine Sulfate 50mg/ml              20ml

                        747789              10/31/98                  Morphine Sulfate 50mg/ml              20ml

 

         Such conduct is in violation of Section 2913.02 of the Ohio Revised Code.

 

(3)      Connie A. Lancz did, on or about October 26, 1997, knowingly make a false statement in a record required by Chapter 3719. or 4729. of the Revised Code, to wit: Connie A. Lancz created a fictitious patient and entered false prescrip­tion information into Drug Corner Pharmacy’s automated data system pursuant to the following prescriptions purportedly written by a physician at MCO Hos­pital:

 

                    Rx Number                Date                                 Drug/Strength                     Quantity

                        667287              10/26/97                  Diazepam 5mg/ml                             10ml

                        667288              10/26/97                  Morphine Sulfate 15mg/ml              40ml

 

         Such conduct is in violation of Section 2925.23(A) of the Ohio Revised Code.

 

(4)      Connie A. Lancz did, from on or about May 29, 1998, through October 26, 1998, knowingly make a false statement in a record required by Chapter 3719. or 4729. of the Revised Code, to wit: Connie A. Lancz created fictitious patients and entered false prescription information into Drug Corner Pharmacy’s auto­mated data system pursuant to the following prescriptions purportedly written by Dr. Daniel J. Radecki:

 

                    Rx Number                Date                                 Drug/Strength                     Quantity

                        718076              05/29/98                  Morphine Sulfate 50mg/ml              20ml

                        719128              06/03/98                  Morphine Sulfate 50mg/ml              20ml

                        720593              06/10/98                  Morphine Sulfate 50mg/ml              20ml

                        721877              06/16/98                  Morphine Sulfate 50mg/ml              20ml

                        723597              06/25/98                  Morphine Sulfate 50mg/ml              20ml

                        724424              06/30/98                  Morphine Sulfate 50mg/ml              20ml

                        725658              07/07/98                  Morphine Sulfate 50mg/ml              20ml

                        727268              07/14/98                  Morphine Sulfate 50mg/ml              20ml

                        729036              07/22/98                  Morphine Sulfate 50mg/ml              20ml

                        729805              07/27/98                  Morphine Sulfate 50mg/ml              20ml

                        731282              08/04/98                  Morphine Sulfate 50mg/ml              20ml

                        732593              08/11/98                  Morphine Sulfate 50mg/ml              20ml

                        733336              08/14/98                  Morphine Sulfate 50mg/ml              20ml

                        734128              08/19/98                  Morphine Sulfate 50mg/ml              20ml

                        736668              09/02/98                  Morphine Sulfate 50mg/ml              20ml

                        737827              09/09/98                  Morphine Sulfate 50mg/ml              20ml

                        739169              09/16/98                  Morphine Sulfate 50mg/ml              20ml

                        740000              09/21/98                  Morphine Sulfate 50mg/ml              20ml

                        740869              09/25/98                  Morphine Sulfate 50mg/ml              20ml

                        741068              09/27/98                  Morphine Sulfate 50mg/ml              20ml

                        742314              10/02/98                  Morphine Sulfate 50mg/ml              20ml

                        743576              10/08/98                  Morphine Sulfate 50mg/ml              20ml

                        744885              10/15/98                  Morphine Sulfate 50mg/ml              20ml

                        744895              10/16/98                  Morphine Sulfate 50mg/ml              20ml

                        745447              10/19/98                  Morphine Sulfate 50mg/ml              20ml

                        746751              10/26/98                  Morphine Sulfate 50mg/ml              20ml

 

         Such conduct is in violation of Section 2925.23(A) of the Ohio Revised Code.

 

(5)      Connie A. Lancz did, from on or about December 22, 1997, through October 31, 1998, knowingly make a false statement in a record required by Chapter 3719. or 4729. of the Revised Code, to wit: Connie A. Lancz created fictitious patients and entered false prescription information into Drug Corner Phar­macy’s automated data system pursuant to the following prescriptions purport­edly written by a physician at St. Luke’s Hospital:

 

                    Rx Number                Date                                 Drug/Strength                     Quantity

                        680947              12/22/97                  Morphine Sulfate 15mg/ml              40ml

                        685554              01/12/98                  Morphine Sulfate 15mg/ml              40ml

                        686827              01/16/98                  Morphine Sulfate 50mg/ml              20ml

                        688369              01/22/98                  Morphine Sulfate 50mg/ml              20ml

                        689966              01/29/98                  Morphine Sulfate 50mg/ml              20ml

                        692957              02/09/98                  Morphine Sulfate 50mg/ml              20ml

                        696487              02/24/98                  Morphine Sulfate 50mg/ml              20ml

                        698676              03/04/98                  Morphine Sulfate 50mg/ml              20ml

                        701786              03/17/98                  Morphine Sulfate 50mg/ml              20ml

                        704891              03/30/98                  Morphine Sulfate 50mg/ml              20ml

                        710205              04/23/98                  Morphine Sulfate 50mg/ml              20ml

                        711914              04/30/98                  Morphine Sulfate 50mg/ml              20ml

                        712555              05/04/98                  Morphine Sulfate 50mg/ml              20ml

                        713575              05/08/98                  Morphine Sulfate 50mg/ml              20ml

                        714223              05/12/98                  Morphine Sulfate 50mg/ml              20ml

                        715820              05/19/98                  Morphine Sulfate 50mg/ml              20ml

                        717842              05/28/98                  Morphine Sulfate 50mg/ml              20ml

                        718593              06/01/98                  Morphine Sulfate 50mg/ml              20ml

                        720359              06/09/98                  Morphine Sulfate 50mg/ml              20ml

                        721502              06/15/98                  Morphine Sulfate 50mg/ml              20ml

                        723598              06/25/98                  Morphine Sulfate 50mg/ml              20ml

                        724425              06/30/98                  Morphine Sulfate 50mg/ml              20ml

                        725945              07/08/98                  Morphine Sulfate 50mg/ml              20ml

                        727542              07/15/98                  Morphine Sulfate 50mg/ml              20ml

                        729233              07/23/98                  Morphine Sulfate 50mg/ml              20ml

                        730029              07/28/98                  Morphine Sulfate 50mg/ml              20ml

                        730501              07/30/98                  Morphine Sulfate 50mg/ml              20ml

                        732855              08/12/98                  Morphine Sulfate 50mg/ml              20ml

                        733617              08/17/98                  Morphine Sulfate 50mg/ml              20ml

                        737084              09/04/98                  Morphine Sulfate 50mg/ml              20ml

                        738267              09/11/98                  Morphine Sulfate 50mg/ml              20ml

                        739590              09/18/98                  Morphine Sulfate 50mg/ml              20ml

                        740433              09/23/98                  Morphine Sulfate 50mg/ml              20ml

                        742313              10/02/98                  Morphine Sulfate 50mg/ml              20ml

                        742781              10/05/98                  Morphine Sulfate 50mg/ml              20ml

                        743795              10/09/98                  Morphine Sulfate 50mg/ml              20ml

                        744891              10/15/98                  Morphine Sulfate 50mg/ml              20ml

                        745474              10/19/98                  Morphine Sulfate 50mg/ml              20ml

                        746135              10/22/98                  Morphine Sulfate 50mg/ml              20ml

                        746812              10/26/98                  Morphine Sulfate 50mg/ml              20ml

                        747789              10/31/98                  Morphine Sulfate 50mg/ml              20ml

 

         Such conduct is in violation of Section 2925.23(A) of the Ohio Revised Code.

 

(6)      Connie A. Lancz is addicted to and/or abusing liquor or drugs or impaired physically or mentally to such a degree as to render her unfit to practice phar­macy, to wit: Connie A. Lancz admitted having a two-year addiction to Mor­phine; Connie A. Lancz has stolen approximately 1,420ml of Morphine Sulfate in a one-year period; and Connie A. Lancz sought treatment from Charter Hos­pital due to her addiction.  Such conduct indicates that Connie A. Lancz falls within the ambit of Section 4729.16(A)(3) of the Ohio Revised Code.

 

CONCLUSIONS OF LAW

 

(1)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraphs (2) through (5) of the Findings of Fact constitute being guilty of a felony and gross immorality as provided in Division (A)(1) of Section 4729.16 of the Ohio Revised Code.

 

(2)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraphs (2) through (5) of the Findings of Fact constitute being guilty of dishonesty and unprofessional conduct in the practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.

 

(3)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraph (6) of the Findings of Fact constitutes being addicted to or abusing liquor or drugs or impaired physically or mentally to such a degree as to render her unfit to practice pharmacy as provided in Division (A)(3) of Sec­tion 4729.16 of the Ohio Revised Code.

 

(4)      Upon consideration of the record as a whole, the State Board of Pharmacy con­cludes that paragraphs (2) through (5) of the Findings of Fact constitute being guilty of willfully violating, conspiring to violate, attempting to violate, or aiding and abetting the violation of provisions of Chapters 2925., 3719., and 4729. of the Revised Code as provided in Division (A)(5) of Section 4729.16 of the Ohio Revised Code.

 

ACTION OF THE BOARD

 

Pursuant to Section 4729.16 of the Ohio Revised Code, and on the basis of the Findings
of Fact and Conclusions of Law set forth above, the State Board of Pharmacy hereby sus­pends indefinitely the pharmacist identification card, No. 03-2-15206, held by Connie A. Lancz and such suspension is effective as of the date of the mailing of this Order.

 

(A)     Connie A. Lancz, pursuant to Rule 4729-9-01(F) of the Ohio Administrative Code, may not be employed by or work in a facility licensed by the Board of Pharmacy to possess or distribute dangerous drugs during such period of suspension.

 

(B)      Connie A. Lancz, pursuant to Section 4729.16(B) of the Ohio Revised Code, must return the identification card and wall certificate to the office of the State Board of Pharmacy within ten days after receipt of this Order.  The identification card and wall certificate should be forwarded by certified mail, return receipt requested.

 

Further, May 1, 2005, or thereafter, the Board will consider any petition filed by Connie A. Lancz for a hearing, pursuant to Ohio Revised Code Chapter 119., for reinstatement.  The Board will only consider reinstatement of the license to practice pharmacy in Ohio if the following conditions have been met:

 

(A)     Connie A. Lancz must obtain, within ninety days of the effective date of this Order, a full psychiatric or psychological evaluation, by a licensed psychiatrist or psychologist, that includes a recommended treatment plan.  Connie A. Lancz must abide by the treatment plan as designed by the professional.

 

(B)      Connie A. Lancz must enter into a contract, signed after the effective date of this Order, with an Ohio Department of Alcohol and Drug Addiction Services (ODADAS) treatment provider or a treatment provider acceptable to the Board for a period of not less than five years and, upon signing, submit a copy of the contract to the Board office.  The contract must provide that:

 

(1)      Random, observed urine drug screens shall be conducted at least once each month.

 

(a)      The urine sample must be given within twelve hours of notification.  The urine screen must include testing for creatinine or specific gravity of the sample as the dilutional standard.

 

(b)      Methylphenidate and alcohol must be added to the standard urine drug screen.  A Breathalyzer may be used to test for alcohol, but the test must be conducted by an appropriately certified individual within twelve hours of notification.

 

(c)      Results of all drug and alcohol screens must be negative.  Any positive results, including those which may have re­sulted from ingestion of food, but excluding false positives which resulted from medication legitimately prescribed, indicates a violation of the contract.

 

(2)      Regular attendance, a minimum of three times per week, at an Alco­holics Anonymous, Narcotics Anonymous, and/or similar support group meeting is required.

 

(3)      The program shall immediately report to the Ohio Board of Pharmacy any violations of the contract and/or lack of cooperation.

 

(C)      Connie A. Lancz must provide, at the reinstatement petition hearing, documen­tation of the following:

 

(1)      Compliance with the licensed psychiatrist's or psychologist's recom­mended treatment plan;

 

(2)      A report by the licensed psychiatrist or psychologist regarding Connie A. Lancz's fitness for readmission into the practice of phar­macy;

 

(3)      Compliance with the contract required above (e.g.-proof of giving the urine sample within twelve hours of notification, copies of all urine screen reports, meeting attendance records, treatment program reports, etc.);

 

(4)      Compliance with the continuing pharmacy education requirements as set forth in Chapter 4729-7 of the Ohio Administrative Code in effect on the date of petitioning the Board for reinstatement;

 

(5)      Compliance with the terms of this Order.

 

THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY.

MOTION CARRIED.

SO ORDERED.

 

                     The motion was seconded by Mr. Kost and approved by the Board (Aye-7/Nay-0).

  3:59 p.m.

                     Mr. Repke moved that the Board receive Per Diem as follows:

 

                           PER DIEM           4/3         4/4         4/5        Total

                           Abele                    1             1             1             3

                           Adelman               1             1             1             3

                           Cavendish            1             1             1             3

                           Eastman               1             1             1             3

                           Giacalone             1             1             1             3

                           Littlejohn             1             1              -             2

                           Kost                      1             1             1             3

                           Neuber                 1             1             1             3

                           Repke                   1             1             1             3

 

                     The motion was seconded by Mrs. Adelman and approved by the Board (Aye-7/Nay-0).

  4:00 p.m.

                     Ms. Abele moved that the meeting be adjourned.  The motion was seconded by Mr. Giacalone and approved (Aye-7/Nay-0).

 

 

 

                    

 

THE BOARD APPROVED THESE MINUTES ON MAY 3, 2000.